{"gene":"MLXIPL","run_date":"2026-06-10T02:59:50","timeline":{"discoveries":[{"year":2001,"finding":"WBSCR14 (MLXIPL/ChREBP) encodes a bHLH-leucine zipper transcription factor that heterodimerizes with Mlx to bind the DNA sequence CACGTG (E-box); association with Mlx represses E-box-dependent transcription, analogous to Mad/Max interactions.","method":"Heterodimer formation and DNA-binding demonstrated by co-immunoprecipitation and electrophoretic mobility shift assay (EMSA); transcriptional repression confirmed by reporter assay","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — direct biochemical binding assay, EMSA, and reporter assay in a single focused study establishing the core molecular mechanism","pmids":["11230181"],"is_preprint":false},{"year":2006,"finding":"ChREBP is activated by increased glucose flux: xylulose 5-phosphate (generated via the pentose phosphate pathway) triggers protein phosphatase 2A (PP2A), which dephosphorylates ChREBP, enabling its nuclear import and transcriptional activation of glycolytic and lipogenic genes.","method":"Biochemical pathway reconstitution; measurement of xylulose 5-phosphate levels; PP2A activity assays; nuclear fractionation in hepatocytes","journal":"Cell metabolism","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — mechanism replicated and reviewed across multiple laboratories; biochemical reconstitution of the Xu-5-P/PP2A/ChREBP axis","pmids":["16890538","18490833"],"is_preprint":false},{"year":2005,"finding":"Polyunsaturated fatty acids (PUFAs: C18:2, C20:5, C22:6) suppress ChREBP activity by increasing ChREBP mRNA decay and blocking its nuclear translocation (independently of AMPK), whereas saturated and monounsaturated fatty acids have no effect. The PUFA-mediated inhibition is primarily through reduction of xylulose 5-phosphate concentrations.","method":"In vivo and in vitro mouse hepatocyte experiments; nuclear fractionation; AMPK-knockout hepatocytes; overexpression of constitutively nuclear ChREBP isoform to rescue PUFA inhibition","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (nuclear fractionation, KO controls, gain-of-function rescue) in a single rigorous study","pmids":["16184193"],"is_preprint":false},{"year":2008,"finding":"ChREBP nuclear export is regulated by phosphorylation-dependent binding to 14-3-3 proteins: 14-3-3 binds an α-helix (residues 125–135) of the N-terminal domain of ChREBP, facilitated by phosphorylation of nearby Ser-140 and Ser-196. Phosphorylation also enables CRM1-mediated nuclear export, whereas dephosphorylated ChREBP interacts with importin-α for nuclear import; 14-3-3 and importin-α compete for ChREBP binding.","method":"In vitro binding assays with synthetic peptides; isothermal titration calorimetry (Kd = 1.1 µM for phospho-Ser-140 peptide); fluorescence spectroscopy; site-directed mutagenesis; nuclear fractionation","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — isothermal calorimetry, mutagenesis, and subcellular fractionation in one rigorous biochemical study","pmids":["18606808"],"is_preprint":false},{"year":2011,"finding":"ChREBP is O-GlcNAcylated in liver cells through interaction with O-GlcNAc transferase (OGT). O-GlcNAcylation stabilizes the ChREBP protein and increases its transcriptional activity toward glycolytic (L-PK) and lipogenic (ACC, FAS, SCD1) target genes in combination with active glucose flux. OGT overexpression increases nuclear ChREBP O-GlcNAc levels and promotes hepatic lipogenesis; OGA overexpression reduces lipogenic protein content and prevents hepatic steatosis in db/db mice.","method":"Co-immunoprecipitation of ChREBP with OGT; adenoviral overexpression/inhibition of OGT and OGA in mouse hepatocytes and in vivo; immunoblot for nuclear ChREBP-OGlcNAc","journal":"Diabetes","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, in vivo genetic gain/loss-of-function with multiple biochemical readouts, replicated in both cell and animal models","pmids":["21471514"],"is_preprint":false},{"year":2011,"finding":"ChREBP imports into the nucleus via a classical bipartite nuclear localization signal (NLS) spanning residues 158–190; importin-α binds this NLS, and replacing Lys-159/Lys-190 with alanine abolishes importin-α binding, glucose-stimulated transcriptional activity, and nuclear localization. A secondary 14-3-3 binding site (α3 helix, residues 170–190, phospho-Ser-196) competes with importin-α.","method":"In vitro binding assays; site-directed mutagenesis (K159A, K190A); nuclear localization assays; transcriptional reporter assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mutagenesis combined with biochemical binding and functional transcriptional assays in one rigorous study","pmids":["21665952"],"is_preprint":false},{"year":2012,"finding":"Crystal structure of 14-3-3β bound to the N-terminal regulatory region of ChREBP at 2.4 Å resolution reveals that ChREBP α2 helix (residues 117–137) binds 14-3-3 in a phosphorylation-independent, novel mode distinct from all previously characterized 14-3-3 interactions; structure-based mutagenesis disrupting this interface abolishes complex formation.","method":"X-ray crystallography (2.4 Å); structure-based mutagenesis; in vitro binding assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — high-resolution crystal structure with mutagenesis validation in a single rigorous study","pmids":["23086940"],"is_preprint":false},{"year":2008,"finding":"ChREBP, but not liver X receptors (LXRs), is required for glucose-induced expression of L-PK, ACC, and FAS in mouse liver. LXR stimulation did not promote ChREBP nuclear localization in the absence of increased intrahepatic glucose flux; glucose induction of these genes was identical in LXRα/β knockout vs. wild-type mice; siRNA silencing of ChREBP in LXRα/β-KO hepatocytes abrogated glucose-induced L-PK and ACC expression.","method":"LXR knockout mice; LXR agonist treatment; siRNA knockdown of ChREBP; FRET analysis of LXR-cofactor interactions; nuclear fractionation","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis (LXR KO) combined with siRNA knockdown, FRET, and nuclear fractionation with orthogonal methods","pmids":["18292813"],"is_preprint":false},{"year":2012,"finding":"ChREBP mediates glucose-stimulated pancreatic β-cell proliferation; depletion of ChREBP decreases glucose-stimulated proliferation and cell-cycle accelerator expression, while overexpression amplifies glucose-stimulated proliferation with increases in cyclin gene expression.","method":"ChREBP knockout mouse β-cells; siRNA knockdown in INS-1 832/13 cells and primary rat/human β-cells; adenoviral overexpression; BrdU/[3H]thymidine incorporation; FACS; qRT-PCR","journal":"Diabetes","confidence":"High","confidence_rationale":"Tier 2 / Strong — loss-of-function (KO, siRNA) and gain-of-function (adenovirus) in multiple cell systems with quantitative proliferation readouts","pmids":["22586588"],"is_preprint":false},{"year":2012,"finding":"A novel, potent ChREBP isoform (ChREBP-β) is transcribed from an alternative promoter in adipose tissue; glucose-mediated activation of canonical ChREBP-α induces ChREBP-β expression. ChREBP-β lacks the N-terminal inhibitory LID domain and is constitutively active. Adipose ChREBP-β is a major determinant of adipose tissue de novo lipogenesis and systemic insulin sensitivity.","method":"Identification of alternative promoter by 5′-RACE; adenoviral overexpression and siRNA knockdown in adipocytes; GLUT4-knockout mouse model; measurement of lipogenic rates","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — discovery of isoform with mechanistic characterization, multiple mouse models, and functional lipogenic/insulin sensitivity readouts","pmids":["22466288"],"is_preprint":false},{"year":2019,"finding":"Host cell factor 1 (HCF-1) is a ChREBP-interacting protein; HCF-1 must first be O-GlcNAcylated in response to glucose to bind ChREBP, after which it recruits OGT to O-GlcNAcylate and activate ChREBP. The HCF-1:ChREBP complex occupies lipogenic gene promoters where HCF-1 regulates H3K4 trimethylation and recruits the histone demethylase PHF2 for epigenetic activation.","method":"Co-immunoprecipitation; ChIP at lipogenic gene promoters; O-GlcNAc site mapping; genetic knockdown; histone modification assays","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP, ChIP, biochemical O-GlcNAcylation studies, and genetic loss-of-function in one rigorous study","pmids":["31227231"],"is_preprint":false},{"year":2017,"finding":"Site-specific O-GlcNAcylation of ChREBP: Ser839 O-GlcNAcylation is essential for Mlx heterodimerization and enhanced DNA-binding activity, and is also crucial for ChREBP nuclear export via strengthening interactions with CRM1 and 14-3-3. Ser614 O-GlcNAcylation was identified by mass spectrometry. Ser514 phosphorylation under high glucose conditions enhances subsequent O-GlcNAcylation of ChREBP.","method":"Chemoenzymatic labeling; metabolic labeling; mass spectrometry; site-directed mutagenesis; co-immunoprecipitation; DNA-binding assays","journal":"Molecular & cellular proteomics","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mass spectrometry site identification combined with mutagenesis and functional assays in one study","pmids":["28450420"],"is_preprint":false},{"year":2010,"finding":"c-Myc is required for ChREBP-dependent activation of glucose-responsive genes; glucose promotes co-recruitment of both ChREBP and c-Myc to the Pklr promoter. Depletion of c-Myc activity abolishes glucose-mediated recruitment of HNF4α, ChREBP, and RNA Pol II without affecting basal expression, constitutively bound HNF1α, or histone acetylation.","method":"Time-course chromatin immunoprecipitation (ChIP); nuclear run-on transcription assay; small molecule inhibition of c-Myc (10058-F4); reporter assays","journal":"Molecular endocrinology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ChIP time-course, nuclear run-on assay, and small-molecule functional epistasis in one study","pmids":["20382893"],"is_preprint":false},{"year":2002,"finding":"ChREBP (WBSCR14/MLXIPL) is present in rat islets and INS-1 cells; glucose stimulates ChREBP transcription (nuclear run-on); overexpression of ChREBP in INS-1 cells produces a left shift in glucose responsiveness of L-PK expression and enhanced L-PK promoter activity; both endogenous and induced ChREBP bind the L-PK promoter in a glucose-dependent manner.","method":"Nuclear run-on experiment; tet-on inducible overexpression system; Northern/Western blot; EMSA (L-PK promoter binding); immunofluorescence","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — nuclear run-on, inducible overexpression, and direct promoter binding assay in INS-1 cells","pmids":["12087089"],"is_preprint":false},{"year":2009,"finding":"ChREBP expression is induced by mitogenic stimulation and is required for efficient cell proliferation. Suppression of ChREBP redirects glucose metabolism from aerobic glycolysis/lipogenesis/nucleotide biosynthesis toward oxidative phosphorylation, activates p53, and causes cell cycle arrest. In vivo, ChREBP suppression leads to p53-dependent reduction in tumor growth.","method":"RNAi-mediated knockdown; metabolic flux measurements; p53 reporter assays; in vivo xenograft tumor model","journal":"PNAS","confidence":"High","confidence_rationale":"Tier 2 / Moderate — loss-of-function with multiple metabolic and cell-cycle readouts, including in vivo tumor model","pmids":["19995986"],"is_preprint":false},{"year":2013,"finding":"In Drosophila, the Mondo (ChREBP ortholog)/Mlx transcriptional network is essential for dietary sugar tolerance; Mlx-null and mondo-reduced larvae have widespread changes in lipid and phospholipid profiles, elevated circulating glucose, and markedly reduced survival on high-sugar diets. Systematic loss-of-function of Mlx target genes identifies Phosphofructokinase 2 (glycolysis), Cabut (KLF transcription factor), and Aldehyde dehydrogenase III as required for sugar tolerance, while fatty acid synthesis is not required and is in fact detrimental.","method":"Genetic null mutants; systematic RNAi loss-of-function screen; lipidomics; metabolite measurements","journal":"PLoS genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — systematic genetic screen with multiple orthogonal metabolic readouts in Drosophila; functional conservation with mammalian ChREBP/Mlx","pmids":["23593032"],"is_preprint":false},{"year":2011,"finding":"ChREBP represses SIRT1 expression in the fed state (high nutrient availability); CREB activates SIRT1 expression during fasting. These opposing transcription factors control SIRT1 expression in a nutrient-sensitive manner across metabolic tissues.","method":"Genetic loss-of-function (ChREBP knockout); chromatin immunoprecipitation; reporter assays; metabolic tissue analysis in multiple nutritional states","journal":"EMBO reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChREBP KO with ChIP, but mechanism of direct repression vs. indirect effects not fully dissected in abstract","pmids":["21836635"],"is_preprint":false},{"year":2016,"finding":"ChREBP is activated by fructose-derived hexose-phosphates in liver and is required for fructose-induced induction of glycolytic, lipogenic, and gluconeogenic (G6pc) genes. ChREBP-driven G6PC activity is a major determinant of hepatic glucose production and reduces glucose-6-phosphate levels. This ChREBP/G6PC axis operates independently of FoxO1 and dominates over insulin suppression.","method":"ChREBP knockout mice; FoxO1-knockout epistasis; hepatic hexose-phosphate measurements; in vivo fructose gavage; G6PC activity assays; conservation confirmed in human cells","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis (KO of ChREBP and FoxO1), enzymatic activity assays, and metabolite measurements with human validation","pmids":["27669460"],"is_preprint":false},{"year":2017,"finding":"ChREBP and PPARα cooperate to regulate glucose-induced FGF21 expression in the liver; PPARα is required for chromatin accessibility at the Fgf21 promoter and for ChREBP binding to the Fgf21 ChoRE. Hepatic PPARα knockout reduces glucose-mediated FGF21 induction, which is restored by active ChREBP re-expression.","method":"ChREBP-KO and PPARα-KO mice; adenoviral ChREBP re-expression; microarray; ChIP for ChREBP at Fgf21 ChoRE; ATAC-seq/chromatin accessibility","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — two KO models with ChIP and chromatin accessibility, plus rescue by ChREBP re-expression","pmids":["29020627"],"is_preprint":false},{"year":2016,"finding":"ChREBP is required for fructose-induced FGF21 secretion; in ChREBP-KO mice, the acute rise in circulating FGF21 following fructose gavage is absent. FGF21 in turn amplifies ChREBP-β and its lipogenic/fructolytic gene targets, constituting a ChREBP–FGF21 feedforward signaling axis.","method":"ChREBP-KO mice; FGF21-KO mice; fructose gavage; plasma FGF21 ELISA; stable isotope tracer de novo lipogenesis measurements","journal":"Molecular metabolism","confidence":"High","confidence_rationale":"Tier 2 / Strong — two independent KO mouse models with quantitative metabolic and endocrine measurements","pmids":["28123933"],"is_preprint":false},{"year":2017,"finding":"Intestinal ChREBP directly binds the Glut5 (Slc2a5) promoter and transcriptionally activates GLUT5 expression; ChREBP and its partner Mlx co-activate the Glut5 promoter. Intestine-specific ChREBP KO leads to fructose intolerance with downregulation of GLUT5 and fructolytic genes, while liver-specific KO does not impair fructose tolerance.","method":"Tissue-specific ChREBP knockout mice (intestine and liver); ChIP on Glut5 promoter; transient transfection/promoter assay with ChREBP + Mlx in Caco-2BBE cells; high-fructose diet phenotyping","journal":"JCI insight","confidence":"High","confidence_rationale":"Tier 2 / Strong — tissue-specific KO epistasis, direct ChIP on target promoter, and functional transactivation assay","pmids":["29263303"],"is_preprint":false},{"year":2018,"finding":"Hormone-sensitive lipase (HSL) physically interacts with ChREBP-α (independently of lipase activity), impairing ChREBP-α nuclear translocation and induction of the constitutively active ChREBP-β isoform. Loss of HSL in adipocytes enhances ChREBP-α nuclear entry, drives ChREBP-β-dependent induction of ELOVL6, increases membrane oleic acid, and enhances insulin signaling.","method":"Co-immunoprecipitation of HSL and ChREBP; genetic inhibition of HSL in human adipocytes and mouse adipose; siRNA knockdown of ChREBP and ELOVL6; nuclear fractionation; phospholipid analysis","journal":"Nature metabolism","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, multiple genetic models (human cells and mouse tissue), nuclear fractionation with lipid functional readout","pmids":["32694809"],"is_preprint":false},{"year":2018,"finding":"ChREBP directly binds to the Glut5 promoter in intestinal cells (confirmed by ChIP) and, together with its heterodimer partner Mlx, activates Glut5 promoter activity. ChREBP KO mice exhibit sucrose intolerance and fructose malabsorption with suppression of fructose transport and metabolism gene expression.","method":"ChREBP KO mice; ChIP on Glut5 promoter in small intestine; co-transfection reporter assay in Caco-2BBE; RT-PCR; gut microbiota analysis","journal":"Metabolism: clinical and experimental","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct ChIP on target promoter, transactivation assay, and genetic KO phenotyping","pmids":["29669261"],"is_preprint":false},{"year":2008,"finding":"BHLHB2/DEC1 constitutes a negative feedback loop with ChREBP in regulating lipogenesis: ChREBP induces Bhlhb2 expression via a functional ChoRE in the Bhlhb2 promoter, and BHLHB2 in turn inhibits ChREBP-mediated induction of Fasn and Lpk by binding to their ChoRE sequences.","method":"Promoter deletion analysis; ChIP assay for BHLHB2 binding to Fasn, Lpk, and Bhlhb2 promoters; overexpression of dominant-active ChREBP; RT-PCR in rat hepatocytes","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP assay and promoter deletion with functional overexpression, single lab","pmids":["18602890"],"is_preprint":false},{"year":2017,"finding":"mTOR associates with the ChREBP-Mlx complex in pancreatic β-cells and inhibits ChREBP transcriptional activity, leading to decreased TXNIP expression. mTOR deficiency in β-cells increases ChREBP-Mlx-driven TXNIP expression and oxidative stress.","method":"Co-immunoprecipitation of mTOR with ChREBP-Mlx; β-cell-specific mTOR knockout mice; TXNIP expression analysis; oxidative stress markers","journal":"The Journal of cell biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP showing complex formation and KO mouse with defined molecular phenotype, single lab","pmids":["28606928"],"is_preprint":false},{"year":2021,"finding":"SIRT6 physically interacts with ChREBP in hepatocytes and suppresses ChREBP transcriptional activity through direct deacetylation, thereby reducing lipogenic gene expression. SIRT6 liver-specific KO leads to elevated ChREBP protein levels and activity.","method":"Co-immunoprecipitation of SIRT6 with ChREBP; deacetylation assay; SIRT6 liver-specific KO mice; Western diet metabolic phenotyping","journal":"Biochimica et biophysica acta. Molecular basis of disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, deacetylation assay, and KO mouse with metabolic readout; single lab","pmids":["34425214"],"is_preprint":false},{"year":2019,"finding":"SMURF2 (E3 ubiquitin ligase) interacts with ChREBP and promotes its ubiquitination and proteasomal degradation. SMURF2 expression inversely correlates with ChREBP levels. AKT acts upstream to suppress SMURF2, thereby protecting ChREBP from degradation. SMURF2-mediated ChREBP degradation reduces aerobic glycolysis and cell proliferation in colorectal cancer cells.","method":"Co-immunoprecipitation; ubiquitination assay; SMURF2 overexpression and knockdown; AKT pharmacological inhibition; metabolic flux measurements","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, ubiquitination assay, and gain/loss-of-function with metabolic readouts in cancer cells; single lab","pmids":["31409643"],"is_preprint":false},{"year":2013,"finding":"Flightless I homolog (FLII), a gelsolin superfamily actin-remodeling protein, physically interacts with ChREBP and negatively regulates its transcriptional activity in cancer cells. The C-terminal 227 amino acids of ChREBP (containing the DNA-binding domain) interact with both LRR and GLD domains of FLII. FLII knockdown increases, and overexpression decreases, ChREBP target gene expression.","method":"Proteomic pulldown to identify interacting proteins; co-immunoprecipitation; co-localization by immunofluorescence; siRNA knockdown and overexpression of FLII","journal":"The international journal of biochemistry & cell biology","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — Co-IP, domain mapping, and functional knockdown/overexpression; single lab","pmids":["24055811"],"is_preprint":false},{"year":2011,"finding":"ChREBP mediates glucose repression of PPARα gene expression in pancreatic β-cells: a constitutively active ChREBP efficiently represses PPARα expression, and siRNA knockdown of ChREBP abrogates glucose repression of PPARα as well as induction of established ChREBP target genes in insulinoma cells and rodent/human islets.","method":"Constitutively active ChREBP overexpression; siRNA knockdown of ChREBP; gene expression analysis in insulinoma cells and primary islets; PPARα promoter characterization","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain- and loss-of-function with defined transcriptional readout in multiple cell systems; single lab","pmids":["21282101"],"is_preprint":false},{"year":2015,"finding":"ChREBP controls PPARγ activity in adipocytes in a fatty acid synthase (FASN)-dependent manner: constitutively active ChREBP activates endogenous PPARγ and promotes adipocyte differentiation by transactivating the PPARγ ligand-binding domain. Reducing ChREBP activity by siRNA, low glucose, or dominant-negative ChREBP impairs differentiation.","method":"Constitutively active ChREBP and dominant-negative ChREBP overexpression; siRNA knockdown; PPARγ ligand-binding domain reporter assay; adipocyte differentiation assay; FASN inhibitor treatment","journal":"Endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain/loss-of-function with reporter assay and differentiation phenotype; mechanism (FASN-dependent lipid ligand generation) is indirectly inferred","pmids":["26181104"],"is_preprint":false},{"year":2018,"finding":"ChREBP regulates hepatic VLDL secretion primarily through transcriptional activation of microsomal triglyceride transfer protein (MTTP); ChREBP overexpression induces Mttp mRNA and protein, while ChREBP KO markedly reduces VLDL particle number and secretion rates. SHP had negligible effect on Mttp expression under normal conditions and did not affect ChREBP transcriptional activity.","method":"Adenoviral overexpression of ChREBP and SHP in rat hepatocytes; promoter reporter assays; Shp-/-, Chrebp-/-, and Chrebp-/-Shp-/- mice; VLDL secretion rate measurements; mRNA/protein analysis","journal":"Nutrients","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple KO mouse models and promoter assays; single lab","pmids":["29518948"],"is_preprint":false},{"year":2016,"finding":"mTORC2 (Rictor) in white adipose tissue controls ChREBP-β expression and de novo lipogenesis: adipocyte-specific deletion of Rictor decreases ChREBP-β expression, reduces adipose DNL, and impairs hepatic insulin sensitivity. mTORC2 promotes ChREBP-β expression in part by controlling glucose uptake.","method":"Adipocyte-specific Rictor knockout mice; ChREBP-β mRNA and lipogenic rate measurements; hepatic insulin sensitivity assays; high-fat diet metabolic phenotyping","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — tissue-specific KO with defined molecular and metabolic phenotypes; mechanism (direct vs. indirect mTORC2 → ChREBP-β) partially established","pmids":["27098609"],"is_preprint":false},{"year":2018,"finding":"ChREBP and Myc cooperatively regulate hepatocyte proliferation and metabolism; ChREBP loss confers a proliferative disadvantage to normal murine hepatocytes (unlike Myc loss), and combined loss further impairs proliferation. ChREBP-controlled transcripts encode enzymes in glycolysis, TCA cycle, and β- and ω-FAO, while Myc-controlled transcripts encode glycolytic, glutaminolytic, and sterol biosynthetic enzymes. Both cooperatively upregulate ribosomal protein genes.","method":"Chrebp-/- and Myc-/- single and double KO mice; hepatoblastoma models; RNA-Seq; metabolic flux studies (oxidative phosphorylation, FAO, pyruvate dehydrogenase)","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis with RNA-Seq and metabolic flux measurements; single lab","pmids":["30087120"],"is_preprint":false},{"year":2024,"finding":"ChREBP acts as an oncogene in hepatocellular carcinoma (HCC) by transcriptionally activating the PI3K regulatory subunit p85α to sustain PI3K/AKT signaling, while simultaneously rerouting glucose and glutamine metabolic fluxes into fatty acid and nucleic acid synthesis. Pharmacological inhibition of ChREBP by SBI-993 suppresses HCC tumor growth in vivo.","method":"ChREBP loss-of-function in HCC cells; ChREBP ChIP-Seq; metabolic flux analysis; p85α promoter assays; SBI-993 pharmacological inhibition in vivo xenograft model","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ChIP-Seq, metabolic flux, promoter assay, and in vivo pharmacological inhibition with tumor growth readout","pmids":["38424041"],"is_preprint":false},{"year":2017,"finding":"Retinol saturase (RetSat) functions upstream of ChREBP in liver: depletion of RetSat reduces ChREBP activity, lowering lipogenic gene expression and hepatic/circulating triglycerides. RetSat's effect on ChREBP is independent of its enzymatic product 13,14-dihydroretinol, suggesting a non-catalytic mechanism.","method":"Liver-specific RetSat depletion in dietary obese mice; ectopic ChREBP expression rescue; 13,14-dihydroretinol supplementation; hepatic TG and blood glucose measurement","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KO with rescue experiment establishing pathway position; mechanism of RetSat→ChREBP connection not fully defined biochemically","pmids":["28855500"],"is_preprint":false},{"year":2020,"finding":"Liver ChREBP protects against fructose-induced glycogenic hepatotoxicity by transcriptionally activating L-type pyruvate kinase (LPK) to channel glucose-6-phosphate away from glycogen synthesis. Liver-specific ChREBP KO causes massive glycogen overload and decreased ATP in fructose-fed mice; hepatic LPK overexpression rescues these phenotypes.","method":"Liver-specific ChREBP KO mice; high-fructose diet; hepatic LPK adenoviral overexpression rescue; G6P measurements; ATP content assay; histology","journal":"Diabetes","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO with mechanistic rescue by target gene overexpression; multiple metabolic measurements","pmids":["31974143"],"is_preprint":false},{"year":2023,"finding":"ChREBP transcriptionally activates hepatocyte growth factor activator (HGFAC) in mouse and human liver (identified via ChIP-Seq); HGFAC enhances lipid and glucose homeostasis partly through activation of hepatic PPARγ. HGFAC-KO mouse phenotypes are concordant with putative loss-of-function human HGFAC variants.","method":"ChREBP ChIP-Seq in mouse liver integrated with human GWAS data; HGFAC gain/loss-of-function mouse models; PPARγ activity assays","journal":"JCI insight","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-Seq with KO mouse models and human genomic integration; PPARγ mechanism is partially inferred","pmids":["36413406"],"is_preprint":false},{"year":2021,"finding":"Thyroid hormone receptor β1 (TRβ1) stimulates hepatic lipogenesis through ChREBP: hepatocyte-specific ChREBP KO abolishes TH-mediated induction of the lipogenic program and impairs regulation of fatty acid oxidation. TH regulates ChREBP activation and its recruitment to DNA. This pathway is conserved in human iPSC-derived hepatocytes.","method":"Hepatocyte-specific TRβ1 KO and ChREBP KO mice; T3 treatment; ChREBP ChIP; lipogenic gene expression; conservation in human iPSC-derived hepatocytes","journal":"Science signaling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — two KO mouse models with ChIP and human cell validation; mechanistic details of TH-ChREBP interaction are partially defined","pmids":["34784250"],"is_preprint":false},{"year":2021,"finding":"ChREBP, together with FoxO1, dually regulates TXNIP (thioredoxin-interacting protein) expression in hepatocytes: ChREBP is required for glucose/fed-state induction of TxNIP in liver, while FoxO1 is required for fasting-state induction. Both transcription factors are identified by ChIP and loss-of-function studies in genetically modified mice.","method":"ChREBP KO and FoxO1 KO mice; ChIP-qPCR; reporter assays; nutritional state manipulation","journal":"iScience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO epistasis with ChIP in two mouse models; single lab","pmids":["33748706"],"is_preprint":false},{"year":2022,"finding":"Hepatocyte KCTD17 promotes ChREBP protein stabilization by inducing degradation of O-GlcNAcase (OGA), thereby increasing O-GlcNAcylated ChREBP levels. SREBP1c induces KCTD17 expression in obesity. Hepatocyte-specific KCTD17 KO in HFD-fed mice improves glucose tolerance and hepatic steatosis; this is reversed by concomitant OGA KO.","method":"CRISPR-Cas9 hepatocyte-specific KO (Kctd17, Oga, double KO); AAV delivery; OGA protein stability assay; ChREBP protein level and target gene analysis; HFD metabolic phenotyping","journal":"Gastroenterology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis with double KO rescue, multiple in vivo metabolic phenotypes, and mechanistic link to OGA/O-GlcNAcylation","pmids":["36402191"],"is_preprint":false},{"year":2022,"finding":"Celastrol directly binds to ChREBP (confirmed by molecular docking, CETSA, DARTS, and mass spectrometry), inhibits ChREBP nuclear translocation, and promotes its proteasomal degradation, thereby repressing TXNIP transcription and ameliorating type 2 diabetes in db/db mice.","method":"Molecular docking; cellular thermal shift assay (CETSA); drug affinity responsive target stability (DARTS); mass spectrometry; nuclear fractionation; gain/loss-of-function (ChREBP and TXNIP); db/db mouse model","journal":"Phytomedicine","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — multiple biophysical binding assays (CETSA, DARTS, MS) confirming direct binding, plus nuclear translocation and in vivo phenotype; single lab","pmids":["36603341"],"is_preprint":false},{"year":2023,"finding":"ChREBP induces mitochondrial fragmentation in kidney podocytes through upregulation of ether phospholipid biosynthesis: ChREBP transcriptionally activates Gnpat (glyceronephosphate O-acyltransferase), a critical enzyme in plasmalogen synthesis, and overexpression of GNPAT reverses the protective effect of ChREBP deficiency on mitochondrial fragmentation.","method":"Inducible podocyte-specific ChREBP KD in db/db mice; lipidomics; GNPAT overexpression rescue; ChREBP ChIP; electron microscopy for mitochondrial morphology","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KD mouse model with lipidomics, ChIP, and genetic rescue experiment; single lab","pmids":["37611830"],"is_preprint":false},{"year":2018,"finding":"ChREBP and its heterodimer partner Mlx cooperate to activate the Glut5 promoter in intestinal cells; ChIP assay demonstrates direct binding of ChREBP to the Glut5 ChoRE in small intestine, but not to the NHE3 promoter.","method":"ChIP assay in mouse small intestine; co-transfection promoter reporter assay in Caco-2BBE cells with ChREBP + Mlx","journal":"Metabolism: clinical and experimental","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct ChIP on target promoter plus transactivation assay; single lab","pmids":["29669261"],"is_preprint":false},{"year":2018,"finding":"ChREBP directly regulates de novo lipogenesis in interplay with SREBP-1c: both transcription factors are required for coordinated postprandial induction of glycolytic and lipogenic mRNAs. ChREBP mediates glucose induction of both glycolytic and lipogenic genes, while SREBP-1c mediates insulin induction of lipogenic genes. ChREBP is also required for normal SREBP-1c mRNA and protein levels in the fed state.","method":"Liver-specific ChREBP KO mice; AAV-mediated nuclear SREBP-1c restoration; Scap-deficient mice (lack active SREBPs); sucrose refeeding paradigm; mRNA and protein measurements","journal":"Journal of lipid research","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis (two KO models), AAV-mediated rescue, and double-conditional approach establishing pathway co-dependence","pmids":["29335275"],"is_preprint":false},{"year":2014,"finding":"High glucose activates nuclear translocation of ChREBP in retinal pigment epithelial (RPE) cells under normoxia, and ChREBP associates with the HIF-1α gene promoter, driving HIF-1α and VEGF expression. This phenomenon is cell-type specific (not observed in lens epithelial or HeLa cells).","method":"Immunofluorescence for ChREBP nuclear localization; ChIP for ChREBP at HIF-1α promoter; ELISA for VEGF; RT-PCR; immunoblot","journal":"Advances in experimental medicine and biology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single ChIP and immunofluorescence study in a single cell type, limited functional follow-up","pmids":["24664750"],"is_preprint":false}],"current_model":"ChREBP (MLXIPL) is a glucose-responsive bHLH-leucine zipper transcription factor that heterodimerizes with Mlx to bind carbohydrate response elements (ChoRE) and transcriptionally activate glycolytic and lipogenic genes; its activity is tightly controlled by nucleocytoplasmic shuttling regulated through phosphorylation (by PKA/AMPK during fasting, reversed by PP2A activated by xylulose 5-phosphate during feeding), interaction of its N-terminal regulatory domain with 14-3-3 proteins (retaining it in the cytosol) and importin-α (driving nuclear import), and post-translational modifications including O-GlcNAcylation (which stabilizes the protein and enhances DNA binding and Mlx heterodimerization) and ubiquitination (mediated by SMURF2 for proteasomal degradation); a potent, constitutively active isoform ChREBP-β lacking the N-terminal inhibitory domain is induced from an alternative promoter by ChREBP-α; in the nucleus ChREBP cooperates with cofactors including HCF-1 (which recruits OGT and the demethylase PHF2 for epigenetic activation), c-Myc, PPARα, and SIRT6 (which deacetylates and suppresses ChREBP), and regulates a broad transcriptional program encompassing lipogenesis, glycolysis, gluconeogenesis (via G6PC), FGF21 secretion, fructose transport (GLUT5), TXNIP, and mitochondrial lipid remodeling across liver, adipose tissue, intestine, pancreatic β-cells, and kidney."},"narrative":{"mechanistic_narrative":"MLXIPL (ChREBP) is a glucose-responsive basic helix-loop-helix-leucine zipper transcription factor that couples cellular carbohydrate flux to the transcriptional control of glycolytic and lipogenic gene programs across liver, adipose, intestine, pancreatic β-cells, and kidney [PMID:11230181, PMID:12087089, PMID:18292813]. It functions as an obligate heterodimer with Mlx, binding E-box/carbohydrate response element (ChoRE) sequences in target promoters such as L-PK and Glut5 [PMID:11230181, PMID:12087089, PMID:29263303]. Its activity is governed by glucose-flux-driven nucleocytoplasmic shuttling: xylulose-5-phosphate activates PP2A to dephosphorylate ChREBP and permit nuclear entry, while polyunsaturated fatty acids suppress activity by lowering xylulose-5-phosphate and blocking nuclear translocation [PMID:16890538, PMID:18490833, PMID:16184193]. Subcellular distribution is set by a competition at the N-terminal regulatory domain in which phosphorylation promotes 14-3-3 binding and CRM1-dependent export, whereas the dephosphorylated form engages importin-α at a bipartite NLS for nuclear import [PMID:18606808, PMID:21665952, PMID:23086940]. Site-specific O-GlcNAcylation, enabled by OGT recruited through glucose-dependent O-GlcNAcylated HCF-1, stabilizes ChREBP and enhances Mlx heterodimerization and DNA binding, with HCF-1 also recruiting PHF2 for epigenetic activation of lipogenic promoters [PMID:21471514, PMID:31227231, PMID:28450420]. Protein abundance is additionally controlled by SMURF2-mediated ubiquitination and by KCTD17, which raises O-GlcNAcylated ChREBP by destabilizing OGA [PMID:31409643, PMID:36402191]. A constitutively active isoform, ChREBP-β, lacking the N-terminal inhibitory domain, is induced from an alternative promoter downstream of glucose-activated ChREBP-α and drives adipose de novo lipogenesis and systemic insulin sensitivity [PMID:22466288]. In the nucleus ChREBP cooperates with c-Myc and PPARα to activate glucose-responsive and FGF21 genes and is restrained by SIRT6 deacetylation [PMID:20382893, PMID:29020627, PMID:34425214]. Beyond lipogenesis, ChREBP governs fructose handling via GLUT5 and the LPK/G6PC axes, drives a ChREBP–FGF21 feedforward loop, controls TXNIP, MTTP-dependent VLDL secretion, and mitochondrial lipid remodeling, and acts as an oncogenic driver of aerobic glycolysis and proliferation in hepatocellular and colorectal cancers [PMID:27669460, PMID:28123933, PMID:29263303, PMID:29518948, PMID:38424041, PMID:37611830].","teleology":[{"year":2001,"claim":"Established the core molecular identity of ChREBP as a bHLH-leucine zipper factor that heterodimerizes with Mlx to bind E-box DNA, defining the obligate partnership underlying all downstream activity.","evidence":"Co-immunoprecipitation, EMSA, and reporter assays demonstrating Mlx heterodimerization and CACGTG binding","pmids":["11230181"],"confidence":"High","gaps":["Initial study reported E-box repression rather than the activation later shown at ChoREs","Did not define glucose-responsiveness mechanism"]},{"year":2002,"claim":"Showed ChREBP is glucose-regulated in pancreatic islet cells and binds the L-PK promoter in a glucose-dependent manner, linking the factor to a physiological metabolic readout.","evidence":"Nuclear run-on, inducible overexpression, and EMSA in INS-1 cells and rat islets","pmids":["12087089"],"confidence":"High","gaps":["Did not define the upstream glucose-sensing biochemistry","Mechanism of nuclear translocation not addressed"]},{"year":2006,"claim":"Defined the upstream metabolic signal activating ChREBP, identifying xylulose-5-phosphate/PP2A-mediated dephosphorylation as the switch enabling nuclear import.","evidence":"Biochemical pathway reconstitution, PP2A activity assays, and nuclear fractionation in hepatocytes","pmids":["16890538","18490833"],"confidence":"High","gaps":["Precise phosphosites controlled by PP2A not fully mapped here","Did not address competing import/export machinery"]},{"year":2005,"claim":"Identified PUFAs as physiological inhibitors acting through reduced xylulose-5-phosphate and blocked nuclear translocation, defining nutrient-specific negative regulation independent of AMPK.","evidence":"Mouse hepatocyte in vivo/in vitro studies, AMPK-KO controls, and constitutively nuclear isoform rescue","pmids":["16184193"],"confidence":"High","gaps":["Did not resolve direct lipid sensing vs. purely metabolite-mediated effects"]},{"year":2008,"claim":"Resolved the molecular basis of cytoplasmic retention versus nuclear import as a phosphorylation-dependent competition between 14-3-3 and importin-α at the N-terminal regulatory domain.","evidence":"Synthetic peptide binding, isothermal titration calorimetry, mutagenesis, and nuclear fractionation","pmids":["18606808"],"confidence":"High","gaps":["Did not yet provide structural detail of the 14-3-3 interface","Kinases responsible for specific phosphosites not all defined"]},{"year":2008,"claim":"Established genetic epistasis placing ChREBP, not LXR, as the essential transducer of glucose-induced lipogenic gene expression in liver.","evidence":"LXRα/β knockout mice, ChREBP siRNA, FRET, and nuclear fractionation","pmids":["18292813"],"confidence":"High","gaps":["Did not exclude LXR contributions under other conditions"]},{"year":2010,"claim":"Defined a cofactor requirement, showing c-Myc is needed for glucose-stimulated co-recruitment of ChREBP and the transcriptional machinery to the Pklr promoter.","evidence":"Time-course ChIP, nuclear run-on, and small-molecule c-Myc inhibition","pmids":["20382893"],"confidence":"High","gaps":["Order of recruitment vs. direct interaction not fully resolved","Generality across other ChoRE genes not tested"]},{"year":2011,"claim":"Mapped the bipartite NLS bound by importin-α and a competing secondary 14-3-3 site, mechanistically detailing the nuclear import determinants required for glucose-stimulated activity.","evidence":"Site-directed mutagenesis (K159A, K190A), binding assays, and transcriptional reporters","pmids":["21665952"],"confidence":"High","gaps":["In vivo contribution of individual residues not tested in animals"]},{"year":2011,"claim":"Identified O-GlcNAcylation as a glucose-coupled modification that stabilizes ChREBP and enhances its lipogenic transcriptional output, linking nutrient flux to protein stability.","evidence":"Reciprocal Co-IP with OGT and in vivo adenoviral OGT/OGA gain/loss-of-function in mouse liver","pmids":["21471514"],"confidence":"High","gaps":["Specific O-GlcNAc sites not mapped in this study","Interplay with phosphorylation not yet defined"]},{"year":2011,"claim":"Extended the regulatory network by showing ChREBP transcriptionally represses SIRT1 in the fed state, positioning it within nutrient-sensitive deacetylase signaling.","evidence":"ChREBP-KO mice, ChIP, and reporter assays across nutritional states","pmids":["21836635"],"confidence":"Medium","gaps":["Direct vs. indirect repression not fully dissected","Single-lab finding"]},{"year":2011,"claim":"Demonstrated ChREBP mediates glucose repression of PPARα in β-cells, broadening its role beyond gene activation to nutrient-dependent gene silencing.","evidence":"Constitutively active ChREBP and siRNA knockdown in insulinoma cells and islets","pmids":["21282101"],"confidence":"Medium","gaps":["Direct promoter binding not definitively shown","Single-lab finding"]},{"year":2012,"claim":"Discovered the constitutively active ChREBP-β isoform induced by ChREBP-α from an alternative promoter, revealing a feedforward amplification mechanism driving adipose lipogenesis and insulin sensitivity.","evidence":"5'-RACE promoter mapping, adenoviral and siRNA manipulation in adipocytes, and GLUT4-KO mouse model","pmids":["22466288"],"confidence":"High","gaps":["Regulation of ChREBP-β promoter choice not fully defined","Tissue-specific control of isoform balance unresolved"]},{"year":2012,"claim":"Provided the crystal structure of 14-3-3β bound to the ChREBP N-terminal regulatory helix, revealing a novel phosphorylation-independent binding mode for cytoplasmic retention.","evidence":"X-ray crystallography at 2.4 Å with structure-based mutagenesis","pmids":["23086940"],"confidence":"High","gaps":["Reconciliation with phosphorylation-dependent 14-3-3 binding at other sites not fully integrated"]},{"year":2012,"claim":"Established ChREBP as a driver of glucose-stimulated β-cell proliferation through cell-cycle gene induction, connecting metabolic sensing to proliferative control.","evidence":"ChREBP-KO, siRNA, and adenoviral overexpression in β-cell systems with proliferation readouts","pmids":["22586588"],"confidence":"High","gaps":["Direct cyclin promoter targets not mapped","Relationship to mitogenic ChREBP role in other tissues unclear"]},{"year":2009,"claim":"Linked ChREBP to proliferation and tumor growth, showing its loss redirects glucose metabolism toward oxidative phosphorylation and activates p53-dependent arrest.","evidence":"RNAi knockdown, metabolic flux analysis, p53 reporters, and xenograft tumor model","pmids":["19995986"],"confidence":"High","gaps":["Mechanism connecting ChREBP loss to p53 activation not defined","Direct vs. metabolic indirect effect on proliferation unresolved"]},{"year":2013,"claim":"Demonstrated evolutionary conservation of the Mondo/Mlx network in dietary sugar tolerance and showed glycolytic, not lipogenic, targets are the critical effectors in Drosophila.","evidence":"Genetic null mutants, systematic RNAi screen, lipidomics, and metabolite measurements","pmids":["23593032"],"confidence":"High","gaps":["Direct translation of dispensable lipogenesis to mammals not established"]},{"year":2013,"claim":"Identified FLII as a direct interactor that negatively regulates ChREBP via its DNA-binding domain, adding an actin-remodeling protein to the repressor set in cancer cells.","evidence":"Proteomic pulldown, Co-IP, domain mapping, and FLII gain/loss-of-function","pmids":["24055811"],"confidence":"Medium","gaps":["Physiological context of FLII regulation not established","Single-lab finding"]},{"year":2008,"claim":"Defined a negative feedback loop in which ChREBP induces BHLHB2/DEC1, which in turn represses ChREBP lipogenic targets, providing autoregulatory damping of lipogenesis.","evidence":"Promoter deletion, ChIP, and dominant-active ChREBP overexpression in rat hepatocytes","pmids":["18602890"],"confidence":"Medium","gaps":["In vivo physiological relevance not established","Single-lab finding"]},{"year":2015,"claim":"Showed ChREBP controls PPARγ activity and adipocyte differentiation in a FASN-dependent manner, implicating ChREBP-driven lipid ligand generation in nuclear receptor activation.","evidence":"Constitutively active/dominant-negative ChREBP, siRNA, PPARγ LBD reporter, and FASN inhibition","pmids":["26181104"],"confidence":"Medium","gaps":["The endogenous FASN-derived ligand not identified","Mechanism inferred indirectly"]},{"year":2016,"claim":"Established ChREBP as the dominant transducer of fructose-induced glycolytic, lipogenic, and gluconeogenic gene expression, including a G6PC axis controlling hepatic glucose production independent of FoxO1.","evidence":"ChREBP-KO and FoxO1-KO epistasis, hexose-phosphate measurements, G6PC activity assays, and human validation","pmids":["27669460"],"confidence":"High","gaps":["Sensing of fructose-derived hexose-phosphates not mechanistically resolved"]},{"year":2016,"claim":"Identified ChREBP as required for fructose-induced FGF21 secretion and revealed a FGF21→ChREBP-β feedforward loop coupling lipogenesis to endocrine signaling.","evidence":"ChREBP-KO and FGF21-KO mice, plasma FGF21 ELISA, and isotope tracer lipogenesis measurements","pmids":["28123933"],"confidence":"High","gaps":["Molecular route of FGF21 feedback onto ChREBP-β not defined"]},{"year":2016,"claim":"Placed mTORC2 upstream of ChREBP-β in white adipose tissue, linking nutrient-sensitive kinase signaling to adipose lipogenesis and hepatic insulin sensitivity.","evidence":"Adipocyte-specific Rictor-KO mice with lipogenic and insulin-sensitivity phenotyping","pmids":["27098609"],"confidence":"Medium","gaps":["Direct vs. glucose-uptake-mediated control of ChREBP-β not fully separated"]},{"year":2017,"claim":"Mapped functional O-GlcNAc sites (Ser839, Ser614) and showed Ser839 modification is essential for Mlx heterodimerization, DNA binding, and CRM1/14-3-3-mediated export, integrating glycosylation with phosphorylation crosstalk.","evidence":"Chemoenzymatic and metabolic labeling, mass spectrometry, mutagenesis, Co-IP, and DNA-binding assays","pmids":["28450420"],"confidence":"High","gaps":["In vivo physiological impact of individual sites not tested"]},{"year":2017,"claim":"Identified PPARα as a required partner establishing chromatin accessibility for ChREBP binding at the Fgf21 ChoRE, defining a cooperative cofactor mechanism for glucose-induced FGF21.","evidence":"ChREBP-KO and PPARα-KO mice, ChIP, ATAC-seq, and ChREBP re-expression rescue","pmids":["29020627"],"confidence":"High","gaps":["Whether PPARα acts at other ChREBP targets not addressed"]},{"year":2017,"claim":"Showed mTOR associates with the ChREBP-Mlx complex in β-cells and restrains TXNIP expression, identifying a kinase-complex interaction modulating oxidative stress.","evidence":"Co-IP and β-cell-specific mTOR-KO mice with TXNIP and oxidative stress readouts","pmids":["28606928"],"confidence":"Medium","gaps":["Direct phosphorylation of complex components not shown","Single-lab finding"]},{"year":2017,"claim":"Positioned retinol saturase (RetSat) as a non-catalytic upstream activator of hepatic ChREBP, expanding the set of upstream regulators of lipogenic ChREBP activity.","evidence":"Liver-specific RetSat depletion with ChREBP rescue and dihydroretinol supplementation","pmids":["28855500"],"confidence":"Medium","gaps":["Biochemical mechanism of RetSat→ChREBP connection undefined"]},{"year":2017,"claim":"Established intestinal ChREBP as a direct activator of the Glut5 fructose transporter, demonstrating tissue-specific control of fructose absorption distinct from hepatic functions.","evidence":"Intestine- and liver-specific ChREBP-KO mice, Glut5 promoter ChIP, and Caco-2BBE transactivation assays","pmids":["29263303"],"confidence":"High","gaps":["Regulation of intestinal ChREBP isoform balance not addressed"]},{"year":2018,"claim":"Confirmed direct ChREBP/Mlx activation of the Glut5 ChoRE in intestine with target specificity, reinforcing the fructose-malabsorption phenotype of ChREBP loss.","evidence":"ChIP on Glut5 vs. NHE3 promoters and Caco-2BBE reporter assays in ChREBP-KO mice","pmids":["29669261"],"confidence":"Medium","gaps":["Single-lab finding overlapping prior intestinal study"]},{"year":2018,"claim":"Defined the ChREBP–SREBP-1c division of labor in postprandial lipogenesis, showing ChREBP mediates glucose induction and supports SREBP-1c levels in the fed state.","evidence":"Liver-specific ChREBP-KO, AAV nuclear SREBP-1c restoration, and Scap-deficient mice","pmids":["29335275"],"confidence":"High","gaps":["Direct physical interaction between the two factors not established"]},{"year":2018,"claim":"Identified MTTP as the principal ChREBP target governing hepatic VLDL secretion, linking ChREBP to lipoprotein export.","evidence":"Adenoviral ChREBP/SHP, promoter reporters, and Chrebp/Shp single and double KO mice with VLDL secretion rates","pmids":["29518948"],"confidence":"Medium","gaps":["Direct ChoRE in Mttp promoter not definitively mapped","Single-lab finding"]},{"year":2018,"claim":"Showed ChREBP and Myc cooperatively program hepatocyte proliferation and metabolism, with distinct and shared transcriptional outputs including ribosomal genes.","evidence":"Chrebp and Myc single/double KO mice, hepatoblastoma models, RNA-Seq, and metabolic flux studies","pmids":["30087120"],"confidence":"Medium","gaps":["Whether cooperation reflects direct co-binding not established","Single-lab finding"]},{"year":2019,"claim":"Defined HCF-1 as a glucose-sensitive cofactor that, after its own O-GlcNAcylation, recruits OGT to ChREBP and PHF2 for epigenetic activation at lipogenic promoters, mechanistically linking glucose to chromatin modification.","evidence":"Co-IP, ChIP, O-GlcNAc site mapping, knockdown, and histone modification assays","pmids":["31227231"],"confidence":"High","gaps":["Generality across non-lipogenic ChREBP targets not tested"]},{"year":2019,"claim":"Identified SMURF2 as the E3 ligase driving ChREBP ubiquitination and degradation, with AKT acting upstream, defining a degradation arm controlling ChREBP-dependent glycolysis in cancer.","evidence":"Co-IP, ubiquitination assays, SMURF2 gain/loss-of-function, and AKT inhibition in colorectal cancer cells","pmids":["31409643"],"confidence":"Medium","gaps":["Ubiquitination site on ChREBP not mapped","Single-lab finding"]},{"year":2020,"claim":"Revealed a protective hepatic function in which ChREBP-driven LPK channels glucose-6-phosphate away from glycogen, preventing fructose-induced glycogenic hepatotoxicity.","evidence":"Liver-specific ChREBP-KO with high-fructose diet and hepatic LPK overexpression rescue","pmids":["31974143"],"confidence":"High","gaps":["Mechanism of G6P partitioning beyond LPK not addressed"]},{"year":2021,"claim":"Established SIRT6 as a direct negative regulator that deacetylates and suppresses ChREBP, restraining lipogenic gene expression.","evidence":"Co-IP, deacetylation assays, and SIRT6 liver-specific KO mice with Western-diet phenotyping","pmids":["34425214"],"confidence":"Medium","gaps":["Specific deacetylated lysines not mapped","Single-lab finding"]},{"year":2021,"claim":"Defined a dual ChREBP/FoxO1 regulation of hepatic TXNIP across fed and fasted states, establishing nutrient-state-specific control of a shared target.","evidence":"ChREBP-KO and FoxO1-KO mice with ChIP-qPCR and reporter assays","pmids":["33748706"],"confidence":"Medium","gaps":["Mechanism of state-specific switching between the two factors unresolved"]},{"year":2021,"claim":"Placed ChREBP downstream of thyroid hormone receptor TRβ1 in driving hepatic lipogenesis, showing TH regulates ChREBP activation and DNA recruitment.","evidence":"Hepatocyte-specific TRβ1-KO and ChREBP-KO mice, T3 treatment, ChREBP ChIP, and human iPSC-hepatocyte validation","pmids":["34784250"],"confidence":"Medium","gaps":["Direct vs. indirect TH-mediated ChREBP activation not fully defined"]},{"year":2022,"claim":"Identified KCTD17 as a stabilizer of ChREBP that acts by promoting OGA degradation to elevate ChREBP O-GlcNAcylation, integrating the SREBP1c–KCTD17 axis with ChREBP stability in obesity.","evidence":"CRISPR hepatocyte-specific single and double KO (Kctd17, Oga), AAV delivery, and HFD metabolic phenotyping","pmids":["36402191"],"confidence":"High","gaps":["Direct KCTD17–OGA mechanism vs. broader effects not fully separated"]},{"year":2022,"claim":"Demonstrated direct small-molecule targeting of ChREBP by celastrol, which blocks nuclear translocation and promotes degradation to repress TXNIP and ameliorate diabetes, providing pharmacological validation of ChREBP as a target.","evidence":"Molecular docking, CETSA, DARTS, mass spectrometry, nuclear fractionation, and db/db mouse model","pmids":["36603341"],"confidence":"Medium","gaps":["Binding site on ChREBP not defined","Selectivity vs. other targets not established"]},{"year":2023,"claim":"Identified a ChREBP target (HGFAC) connecting glucose-sensing transcription to systemic lipid and glucose homeostasis via hepatic PPARγ, with concordance between mouse and human genetics.","evidence":"ChREBP ChIP-Seq integrated with human GWAS and HGFAC gain/loss-of-function mouse models","pmids":["36413406"],"confidence":"Medium","gaps":["PPARγ activation mechanism partially inferred","Single-lab finding"]},{"year":2023,"claim":"Linked ChREBP to mitochondrial morphology in kidney podocytes through transcriptional activation of Gnpat and ether phospholipid synthesis, extending its remit to organelle remodeling in diabetic nephropathy.","evidence":"Inducible podocyte-specific ChREBP knockdown in db/db mice, lipidomics, ChIP, GNPAT rescue, and EM","pmids":["37611830"],"confidence":"Medium","gaps":["Generality of ether-lipid mechanism to other tissues unknown","Single-lab finding"]},{"year":2024,"claim":"Defined ChREBP as an oncogenic driver in hepatocellular carcinoma that sustains PI3K/AKT signaling via p85α and reroutes glucose/glutamine flux, with pharmacological inhibition suppressing tumor growth.","evidence":"ChREBP loss-of-function, ChIP-Seq, metabolic flux analysis, p85α promoter assays, and SBI-993 in vivo xenografts","pmids":["38424041"],"confidence":"High","gaps":["Therapeutic window and selectivity of inhibition not established"]},{"year":null,"claim":"How the multiple regulatory layers — phosphorylation, O-GlcNAcylation, acetylation, 14-3-3/importin shuttling, ubiquitination, and cofactor recruitment — are integrated in real time to set ChREBP output in a tissue- and nutrient-specific manner remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified quantitative model linking PTM crosstalk to transcriptional output","Tissue-specific isoform and cofactor balance not systematically mapped","Structural basis of full-length ChREBP-Mlx ChoRE engagement undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,7,13,17,20,33]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,11,13,20]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[1,3,5,13]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[2,3,5,21]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[1,4,7,17,35,43]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,10,12,18]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[1,2,17]}],"complexes":["ChREBP-Mlx heterodimer"],"partners":["MLX","YWHAB","HCFC1","OGT","MYC","SIRT6","SMURF2","LIPE"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9NP71","full_name":"Carbohydrate-responsive element-binding protein","aliases":["Class D basic helix-loop-helix protein 14","bHLHd14","MLX interactor","MLX-interacting protein-like","WS basic-helix-loop-helix leucine zipper protein","WS-bHLH","Williams-Beuren syndrome chromosomal region 14 protein"],"length_aa":852,"mass_kda":93.1,"function":"Glucose-responsive transcription activator that regulates fatty acid synthesis and glycolysis. Key determinant of systemic insulin sensitivity and glucose homeostasis. Important for the expression of fatty acid synthetic enzymes, including PC/Pcx, APOC4/Acl, ACACA/Acc1 and FASN/Fas (By similarity). Important for glucose-induced expression of L-type pyruvate kinase/PKLR (By similarity). Binds to the canonical and non-canonical E box DNA sequences 5'-CACGTG-3' and 5'-CACGCG-3' (By similarity). May also act as a transcriptional repressor (By similarity)","subcellular_location":"Cytoplasm; Nucleus","url":"https://www.uniprot.org/uniprotkb/Q9NP71/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/MLXIPL","classification":"Not Classified","n_dependent_lines":8,"n_total_lines":1208,"dependency_fraction":0.006622516556291391},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/MLXIPL","total_profiled":1310},"omim":[{"mim_id":"605678","title":"MLX-INTERACTING PROTEIN-LIKE; MLXIPL","url":"https://www.omim.org/entry/605678"},{"mim_id":"138190","title":"SOLUTE CARRIER FAMILY 2 (FACILITATED GLUCOSE TRANSPORTER), MEMBER 4; SLC2A4","url":"https://www.omim.org/entry/138190"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"liver","ntpm":546.1}],"url":"https://www.proteinatlas.org/search/MLXIPL"},"hgnc":{"alias_symbol":["WS-bHLH","MIO","CHREBP","MONDOB","bHLHd14"],"prev_symbol":["WBSCR14"]},"alphafold":{"accession":"Q9NP71","domains":[{"cath_id":"-","chopping":"85-150","consensus_level":"medium","plddt":68.8,"start":85,"end":150},{"cath_id":"4.10.280,4.10.280","chopping":"661-680_688-735","consensus_level":"medium","plddt":92.4334,"start":661,"end":735},{"cath_id":"-","chopping":"739-846","consensus_level":"high","plddt":87.9013,"start":739,"end":846}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NP71","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NP71-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NP71-F1-predicted_aligned_error_v6.png","plddt_mean":53.84},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=MLXIPL","jax_strain_url":"https://www.jax.org/strain/search?query=MLXIPL"},"sequence":{"accession":"Q9NP71","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9NP71.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9NP71/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NP71"}},"corpus_meta":[{"pmid":"22466288","id":"PMC_22466288","title":"A novel ChREBP isoform in adipose tissue regulates systemic glucose metabolism.","date":"2012","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/22466288","citation_count":495,"is_preprint":false},{"pmid":"16890538","id":"PMC_16890538","title":"Carbohydrate response element binding protein, ChREBP, a transcription factor coupling hepatic glucose utilization and lipid synthesis.","date":"2006","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/16890538","citation_count":417,"is_preprint":false},{"pmid":"18193046","id":"PMC_18193046","title":"Genome-wide scan identifies variation in MLXIPL associated with plasma triglycerides.","date":"2008","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18193046","citation_count":260,"is_preprint":false},{"pmid":"15733741","id":"PMC_15733741","title":"Carbohydrate responsive element binding protein (ChREBP) and sterol regulatory element binding protein-1c (SREBP-1c): two key regulators of glucose metabolism and lipid synthesis in liver.","date":"2005","source":"Biochimie","url":"https://pubmed.ncbi.nlm.nih.gov/15733741","citation_count":256,"is_preprint":false},{"pmid":"23443556","id":"PMC_23443556","title":"De novo lipogenesis in human fat and liver is linked to ChREBP-β and metabolic health.","date":"2013","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/23443556","citation_count":256,"is_preprint":false},{"pmid":"24222088","id":"PMC_24222088","title":"Transcriptional control of hepatic lipid metabolism by SREBP and ChREBP.","date":"2013","source":"Seminars in liver disease","url":"https://pubmed.ncbi.nlm.nih.gov/24222088","citation_count":234,"is_preprint":false},{"pmid":"16184193","id":"PMC_16184193","title":"Polyunsaturated fatty acids suppress glycolytic and lipogenic genes through the inhibition of ChREBP nuclear protein translocation.","date":"2005","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/16184193","citation_count":230,"is_preprint":false},{"pmid":"17428181","id":"PMC_17428181","title":"ChREBP, a transcriptional regulator of glucose and lipid metabolism.","date":"2007","source":"Annual review of nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/17428181","citation_count":210,"is_preprint":false},{"pmid":"29335275","id":"PMC_29335275","title":"Interplay between ChREBP and SREBP-1c coordinates postprandial glycolysis and lipogenesis in livers of mice.","date":"2018","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/29335275","citation_count":190,"is_preprint":false},{"pmid":"28768172","id":"PMC_28768172","title":"Sweet Sixteenth for ChREBP: Established Roles and Future Goals.","date":"2017","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/28768172","citation_count":180,"is_preprint":false},{"pmid":"27669460","id":"PMC_27669460","title":"ChREBP regulates fructose-induced glucose production independently of insulin signaling.","date":"2016","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/27669460","citation_count":176,"is_preprint":false},{"pmid":"18490833","id":"PMC_18490833","title":"ChREBP: a glucose-activated transcription factor involved in the development of metabolic syndrome.","date":"2008","source":"Endocrine journal","url":"https://pubmed.ncbi.nlm.nih.gov/18490833","citation_count":173,"is_preprint":false},{"pmid":"21471514","id":"PMC_21471514","title":"O-GlcNAcylation increases ChREBP protein content and transcriptional activity in the liver.","date":"2011","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/21471514","citation_count":173,"is_preprint":false},{"pmid":"23597489","id":"PMC_23597489","title":"Novel insights into ChREBP regulation and function.","date":"2013","source":"Trends in endocrinology and metabolism: TEM","url":"https://pubmed.ncbi.nlm.nih.gov/23597489","citation_count":165,"is_preprint":false},{"pmid":"18292813","id":"PMC_18292813","title":"ChREBP, but not LXRs, is required for the induction of glucose-regulated genes in mouse liver.","date":"2008","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/18292813","citation_count":163,"is_preprint":false},{"pmid":"12110366","id":"PMC_12110366","title":"Carbohydrate responsive element-binding protein (ChREBP): a key regulator of glucose metabolism and fat storage.","date":"2002","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/12110366","citation_count":155,"is_preprint":false},{"pmid":"27098609","id":"PMC_27098609","title":"Adipose tissue mTORC2 regulates ChREBP-driven de novo lipogenesis and hepatic glucose metabolism.","date":"2016","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/27098609","citation_count":149,"is_preprint":false},{"pmid":"28123933","id":"PMC_28123933","title":"A critical role for ChREBP-mediated FGF21 secretion in hepatic fructose metabolism.","date":"2016","source":"Molecular metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/28123933","citation_count":142,"is_preprint":false},{"pmid":"21836635","id":"PMC_21836635","title":"CREB and ChREBP oppositely regulate SIRT1 expression in response to energy availability.","date":"2011","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/21836635","citation_count":140,"is_preprint":false},{"pmid":"31275349","id":"PMC_31275349","title":"Carbohydrate Sensing Through the Transcription Factor ChREBP.","date":"2019","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/31275349","citation_count":132,"is_preprint":false},{"pmid":"19995986","id":"PMC_19995986","title":"The glucose-responsive transcription factor ChREBP contributes to glucose-dependent anabolic synthesis and cell proliferation.","date":"2009","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/19995986","citation_count":119,"is_preprint":false},{"pmid":"17716660","id":"PMC_17716660","title":"Role of ChREBP in hepatic steatosis and insulin resistance.","date":"2007","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/17716660","citation_count":115,"is_preprint":false},{"pmid":"29020627","id":"PMC_29020627","title":"A Specific ChREBP and PPARα Cross-Talk Is Required for the Glucose-Mediated FGF21 Response.","date":"2017","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/29020627","citation_count":107,"is_preprint":false},{"pmid":"33343508","id":"PMC_33343508","title":"ChREBP-Mediated Regulation of Lipid Metabolism: Involvement of the Gut Microbiota, Liver, and Adipose Tissue.","date":"2020","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/33343508","citation_count":105,"is_preprint":false},{"pmid":"22586588","id":"PMC_22586588","title":"ChREBP mediates glucose-stimulated pancreatic β-cell proliferation.","date":"2012","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/22586588","citation_count":102,"is_preprint":false},{"pmid":"11230181","id":"PMC_11230181","title":"WBSCR14, a gene mapping to the Williams--Beuren syndrome deleted region, is a new member of the Mlx transcription factor network.","date":"2001","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11230181","citation_count":93,"is_preprint":false},{"pmid":"18606808","id":"PMC_18606808","title":"Regulation of nuclear import/export of carbohydrate response element-binding protein (ChREBP): interaction of an alpha-helix of ChREBP with the 14-3-3 proteins and regulation by phosphorylation.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18606808","citation_count":92,"is_preprint":false},{"pmid":"12087089","id":"PMC_12087089","title":"ChREBP rather than USF2 regulates glucose stimulation of endogenous L-pyruvate kinase expression in insulin-secreting cells.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12087089","citation_count":91,"is_preprint":false},{"pmid":"23593032","id":"PMC_23593032","title":"Mondo/ChREBP-Mlx-regulated transcriptional network is essential for dietary sugar tolerance in Drosophila.","date":"2013","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23593032","citation_count":91,"is_preprint":false},{"pmid":"31809000","id":"PMC_31809000","title":"Long non-coding RNA (lncRNA) H19 induces hepatic steatosis through activating MLXIPL and mTORC1 networks in hepatocytes.","date":"2019","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31809000","citation_count":83,"is_preprint":false},{"pmid":"29263303","id":"PMC_29263303","title":"Intestinal, but not hepatic, ChREBP is required for fructose tolerance.","date":"2017","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/29263303","citation_count":79,"is_preprint":false},{"pmid":"19799862","id":"PMC_19799862","title":"Replacing dietary glucose with fructose increases ChREBP activity and SREBP-1 protein in rat liver nucleus.","date":"2009","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/19799862","citation_count":79,"is_preprint":false},{"pmid":"22382520","id":"PMC_22382520","title":"Carbohydrate response element-binding protein (ChREBP) plays a pivotal role in beta cell glucotoxicity.","date":"2012","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/22382520","citation_count":75,"is_preprint":false},{"pmid":"24449882","id":"PMC_24449882","title":"ChREBP, a glucose-responsive transcriptional factor, enhances glucose metabolism to support biosynthesis in human cytomegalovirus-infected cells.","date":"2014","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/24449882","citation_count":73,"is_preprint":false},{"pmid":"37055547","id":"PMC_37055547","title":"The role of ChREBP in carbohydrate sensing and NAFLD development.","date":"2023","source":"Nature reviews. Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/37055547","citation_count":70,"is_preprint":false},{"pmid":"16614395","id":"PMC_16614395","title":"Hepatic gene regulation by glucose and polyunsaturated fatty acids: a role for ChREBP.","date":"2006","source":"The Journal of nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/16614395","citation_count":68,"is_preprint":false},{"pmid":"21453770","id":"PMC_21453770","title":"Cross-regulation of hepatic glucose metabolism via ChREBP and nuclear receptors.","date":"2011","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/21453770","citation_count":66,"is_preprint":false},{"pmid":"10780788","id":"PMC_10780788","title":"WBSCR14, a putative transcription factor gene deleted in Williams-Beuren syndrome: complete characterisation of the human gene and the mouse ortholog.","date":"2000","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/10780788","citation_count":60,"is_preprint":false},{"pmid":"28606928","id":"PMC_28606928","title":"mTOR controls ChREBP transcriptional activity and pancreatic β cell survival under diabetic stress.","date":"2017","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/28606928","citation_count":60,"is_preprint":false},{"pmid":"27919710","id":"PMC_27919710","title":"The transcription factor carbohydrate-response element-binding protein (ChREBP): A possible link between metabolic disease and cancer.","date":"2016","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/27919710","citation_count":59,"is_preprint":false},{"pmid":"36352530","id":"PMC_36352530","title":"Aberrant elevation of FTO levels promotes liver steatosis by decreasing the m6A methylation and increasing the stability of SREBF1 and ChREBP mRNAs.","date":"2023","source":"Journal of molecular cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/36352530","citation_count":57,"is_preprint":false},{"pmid":"21840420","id":"PMC_21840420","title":"ChREBP expression in the liver, adipose tissue and differentiated preadipocytes in human obesity.","date":"2011","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/21840420","citation_count":56,"is_preprint":false},{"pmid":"26181104","id":"PMC_26181104","title":"The Glucose Sensor ChREBP Links De Novo Lipogenesis to PPARγ Activity and Adipocyte Differentiation.","date":"2015","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/26181104","citation_count":55,"is_preprint":false},{"pmid":"23604004","id":"PMC_23604004","title":"Recent progress on the role of ChREBP in glucose and lipid metabolism.","date":"2013","source":"Endocrine journal","url":"https://pubmed.ncbi.nlm.nih.gov/23604004","citation_count":53,"is_preprint":false},{"pmid":"33812993","id":"PMC_33812993","title":"Adaptive and maladaptive roles for ChREBP in the liver and pancreatic islets.","date":"2021","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/33812993","citation_count":51,"is_preprint":false},{"pmid":"18602890","id":"PMC_18602890","title":"Regulation of lipogenesis via BHLHB2/DEC1 and ChREBP feedback looping.","date":"2008","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/18602890","citation_count":50,"is_preprint":false},{"pmid":"38424041","id":"PMC_38424041","title":"The transcription factor ChREBP Orchestrates liver carcinogenesis by coordinating the PI3K/AKT signaling and cancer metabolism.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/38424041","citation_count":49,"is_preprint":false},{"pmid":"20382893","id":"PMC_20382893","title":"c-Myc is required for the CHREBP-dependent activation of glucose-responsive genes.","date":"2010","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/20382893","citation_count":47,"is_preprint":false},{"pmid":"32694809","id":"PMC_32694809","title":"Interaction between hormone-sensitive lipase and ChREBP in fat cells controls insulin sensitivity.","date":"2018","source":"Nature metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/32694809","citation_count":46,"is_preprint":false},{"pmid":"31227231","id":"PMC_31227231","title":"HCF-1 Regulates De Novo Lipogenesis through a Nutrient-Sensitive Complex with ChREBP.","date":"2019","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/31227231","citation_count":46,"is_preprint":false},{"pmid":"28403938","id":"PMC_28403938","title":"MondoA/ChREBP: The usual suspects of transcriptional glucose sensing; Implication in pathophysiology.","date":"2017","source":"Metabolism: clinical and experimental","url":"https://pubmed.ncbi.nlm.nih.gov/28403938","citation_count":44,"is_preprint":false},{"pmid":"29669261","id":"PMC_29669261","title":"ChREBP deficiency leads to diarrhea-predominant irritable bowel syndrome.","date":"2018","source":"Metabolism: clinical and experimental","url":"https://pubmed.ncbi.nlm.nih.gov/29669261","citation_count":42,"is_preprint":false},{"pmid":"26248218","id":"PMC_26248218","title":"FABP4-Cre Mediated Expression of Constitutively Active ChREBP Protects Against Obesity, Fatty Liver, and Insulin Resistance.","date":"2015","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/26248218","citation_count":42,"is_preprint":false},{"pmid":"26808438","id":"PMC_26808438","title":"ChREBP Regulates Itself and Metabolic Genes Implicated in Lipid Accumulation in β-Cell Line.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26808438","citation_count":41,"is_preprint":false},{"pmid":"26525342","id":"PMC_26525342","title":"Integration of ChREBP-Mediated Glucose Sensing into Whole Body Metabolism.","date":"2015","source":"Physiology (Bethesda, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/26525342","citation_count":41,"is_preprint":false},{"pmid":"32738448","id":"PMC_32738448","title":"Reduced Nogo expression inhibits diet-induced metabolic disorders by regulating ChREBP and insulin activity.","date":"2020","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/32738448","citation_count":40,"is_preprint":false},{"pmid":"22227283","id":"PMC_22227283","title":"Isoflavones as a smart curer for non-alcoholic fatty liver disease and pathological adiposity via ChREBP and Wnt signaling.","date":"2011","source":"Preventive medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22227283","citation_count":40,"is_preprint":false},{"pmid":"34425214","id":"PMC_34425214","title":"SIRT6 controls hepatic lipogenesis by suppressing LXR, ChREBP, and SREBP1.","date":"2021","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/34425214","citation_count":40,"is_preprint":false},{"pmid":"31409643","id":"PMC_31409643","title":"The ubiquitination ligase SMURF2 reduces aerobic glycolysis and colorectal cancer cell proliferation by promoting ChREBP ubiquitination and degradation.","date":"2019","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31409643","citation_count":39,"is_preprint":false},{"pmid":"30158026","id":"PMC_30158026","title":"Recent insights into the role of ChREBP in intestinal fructose absorption and metabolism.","date":"2018","source":"BMB reports","url":"https://pubmed.ncbi.nlm.nih.gov/30158026","citation_count":38,"is_preprint":false},{"pmid":"28855500","id":"PMC_28855500","title":"Retinol saturase coordinates liver metabolism by regulating ChREBP activity.","date":"2017","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/28855500","citation_count":37,"is_preprint":false},{"pmid":"21282101","id":"PMC_21282101","title":"ChREBP mediates glucose repression of peroxisome proliferator-activated receptor alpha expression in pancreatic beta-cells.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21282101","citation_count":37,"is_preprint":false},{"pmid":"29534502","id":"PMC_29534502","title":"ChREBP-Knockout Mice Show Sucrose Intolerance and Fructose Malabsorption.","date":"2018","source":"Nutrients","url":"https://pubmed.ncbi.nlm.nih.gov/29534502","citation_count":36,"is_preprint":false},{"pmid":"31974143","id":"PMC_31974143","title":"Liver ChREBP Protects Against Fructose-Induced Glycogenic Hepatotoxicity by Regulating L-Type Pyruvate Kinase.","date":"2020","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/31974143","citation_count":36,"is_preprint":false},{"pmid":"30087120","id":"PMC_30087120","title":"Myc and ChREBP transcription factors cooperatively regulate normal and neoplastic hepatocyte proliferation in mice.","date":"2018","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30087120","citation_count":34,"is_preprint":false},{"pmid":"23086940","id":"PMC_23086940","title":"Structural characterization of a unique interface between carbohydrate response element-binding protein (ChREBP) and 14-3-3β protein.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23086940","citation_count":34,"is_preprint":false},{"pmid":"30405056","id":"PMC_30405056","title":"ChREBP Reciprocally Regulates Liver and Plasma Triacylglycerol Levels in Different Manners.","date":"2018","source":"Nutrients","url":"https://pubmed.ncbi.nlm.nih.gov/30405056","citation_count":33,"is_preprint":false},{"pmid":"21665952","id":"PMC_21665952","title":"Importin-alpha protein binding to a nuclear localization signal of carbohydrate response element-binding protein (ChREBP).","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21665952","citation_count":33,"is_preprint":false},{"pmid":"34784250","id":"PMC_34784250","title":"Thyroid hormone signaling promotes hepatic lipogenesis through the transcription factor ChREBP.","date":"2021","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/34784250","citation_count":33,"is_preprint":false},{"pmid":"25628602","id":"PMC_25628602","title":"O-GlcNAcylation Links ChREBP and FXR to Glucose-Sensing.","date":"2015","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/25628602","citation_count":31,"is_preprint":false},{"pmid":"33462196","id":"PMC_33462196","title":"Single-cell analysis reveals the intra-tumor heterogeneity and identifies MLXIPL as a biomarker in the cellular trajectory of hepatocellular carcinoma.","date":"2021","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/33462196","citation_count":31,"is_preprint":false},{"pmid":"24664750","id":"PMC_24664750","title":"High glucose activates ChREBP-mediated HIF-1α and VEGF expression in human RPE cells under normoxia.","date":"2014","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/24664750","citation_count":31,"is_preprint":false},{"pmid":"31542428","id":"PMC_31542428","title":"Quercetin inhibition of SREBPs and ChREBP expression results in reduced cholesterol and fatty acid synthesis in C6 glioma cells.","date":"2019","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/31542428","citation_count":31,"is_preprint":false},{"pmid":"37049617","id":"PMC_37049617","title":"Recent Progress on Fructose Metabolism-Chrebp, Fructolysis, and Polyol Pathway.","date":"2023","source":"Nutrients","url":"https://pubmed.ncbi.nlm.nih.gov/37049617","citation_count":30,"is_preprint":false},{"pmid":"37770579","id":"PMC_37770579","title":"Acetyl-CoA synthetase 2 promotes diabetic renal tubular injury in mice by rewiring fatty acid metabolism through SIRT1/ChREBP pathway.","date":"2023","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/37770579","citation_count":30,"is_preprint":false},{"pmid":"32144313","id":"PMC_32144313","title":"Carbohydrate response element binding protein (ChREBP) correlates with colon cancer progression and contributes to cell proliferation.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/32144313","citation_count":30,"is_preprint":false},{"pmid":"30418986","id":"PMC_30418986","title":"Carvacrol reduces adipogenic differentiation by modulating autophagy and ChREBP expression.","date":"2018","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/30418986","citation_count":27,"is_preprint":false},{"pmid":"32208359","id":"PMC_32208359","title":"ChREBP-β regulates thermogenesis in brown adipose tissue.","date":"2020","source":"The Journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/32208359","citation_count":27,"is_preprint":false},{"pmid":"29098321","id":"PMC_29098321","title":"Sugar-sweetened beverage intake associations with fasting glucose and insulin concentrations are not modified by selected genetic variants in a ChREBP-FGF21 pathway: a meta-analysis.","date":"2017","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/29098321","citation_count":27,"is_preprint":false},{"pmid":"35124887","id":"PMC_35124887","title":"ChREBP-driven DNL and PNPLA3 Expression Induced by Liquid Fructose are Essential in the Production of Fatty Liver and Hypertriglyceridemia in a High-Fat Diet-Fed Rat Model.","date":"2022","source":"Molecular nutrition & food research","url":"https://pubmed.ncbi.nlm.nih.gov/35124887","citation_count":26,"is_preprint":false},{"pmid":"25933497","id":"PMC_25933497","title":"ChREBP binding and histone modifications modulate hepatic expression of the Fasn gene in a metabolic syndrome rat model.","date":"2015","source":"Nutrition (Burbank, Los Angeles County, Calif.)","url":"https://pubmed.ncbi.nlm.nih.gov/25933497","citation_count":25,"is_preprint":false},{"pmid":"28450420","id":"PMC_28450420","title":"Validation, Identification, and Biological Consequences of the Site-specific O-GlcNAcylation Dynamics of Carbohydrate-responsive Element-binding Protein (ChREBP).","date":"2017","source":"Molecular & cellular proteomics : MCP","url":"https://pubmed.ncbi.nlm.nih.gov/28450420","citation_count":25,"is_preprint":false},{"pmid":"29077876","id":"PMC_29077876","title":"T3 and Glucose Coordinately Stimulate ChREBP-Mediated Ucp1 Expression in Brown Adipocytes From Male Mice.","date":"2018","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/29077876","citation_count":24,"is_preprint":false},{"pmid":"39538358","id":"PMC_39538358","title":"Acute hyperglycemia exacerbates neuroinflammation and cognitive impairment in sepsis-associated encephalopathy by mediating the ChREBP/HIF-1α pathway.","date":"2024","source":"European journal of medical research","url":"https://pubmed.ncbi.nlm.nih.gov/39538358","citation_count":23,"is_preprint":false},{"pmid":"36413406","id":"PMC_36413406","title":"HGFAC is a ChREBP-regulated hepatokine that enhances glucose and lipid homeostasis.","date":"2023","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/36413406","citation_count":23,"is_preprint":false},{"pmid":"29518948","id":"PMC_29518948","title":"ChREBP Rather Than SHP Regulates Hepatic VLDL Secretion.","date":"2018","source":"Nutrients","url":"https://pubmed.ncbi.nlm.nih.gov/29518948","citation_count":23,"is_preprint":false},{"pmid":"31782782","id":"PMC_31782782","title":"TXNIP induced by MondoA, rather than ChREBP, suppresses cervical cancer cell proliferation, migration and invasion.","date":"2020","source":"Journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31782782","citation_count":23,"is_preprint":false},{"pmid":"32470978","id":"PMC_32470978","title":"Dietary Glucose Increases Glucose Absorption and Lipid Deposition via SGLT1/2 Signaling and Acetylated ChREBP in the Intestine and Isolated Intestinal Epithelial Cells of Yellow Catfish.","date":"2020","source":"The Journal of nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/32470978","citation_count":22,"is_preprint":false},{"pmid":"35538534","id":"PMC_35538534","title":"Inhibition of ChREBP ubiquitination via the ROS/Akt-dependent downregulation of Smurf2 contributes to lysophosphatidic acid-induced fibrosis in renal mesangial cells.","date":"2022","source":"Journal of biomedical science","url":"https://pubmed.ncbi.nlm.nih.gov/35538534","citation_count":22,"is_preprint":false},{"pmid":"36828294","id":"PMC_36828294","title":"ChREBP-β/TXNIP aggravates frucose-induced renal injury through triggering ferroptosis of renal tubular epithelial cells.","date":"2023","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36828294","citation_count":20,"is_preprint":false},{"pmid":"33748706","id":"PMC_33748706","title":"Dual regulation of TxNIP by ChREBP and FoxO1 in liver.","date":"2021","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/33748706","citation_count":20,"is_preprint":false},{"pmid":"36603341","id":"PMC_36603341","title":"Celastrol targets the ChREBP-TXNIP axis to ameliorates type 2 diabetes mellitus.","date":"2022","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/36603341","citation_count":20,"is_preprint":false},{"pmid":"24055811","id":"PMC_24055811","title":"Flightless I homolog negatively regulates ChREBP activity in cancer cells.","date":"2013","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/24055811","citation_count":20,"is_preprint":false},{"pmid":"31623194","id":"PMC_31623194","title":"Glucose-Sensing Transcription Factor MondoA/ChREBP as Targets for Type 2 Diabetes: Opportunities and Challenges.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31623194","citation_count":19,"is_preprint":false},{"pmid":"32467232","id":"PMC_32467232","title":"Role for carbohydrate response element-binding protein (ChREBP) in high glucose-mediated repression of long noncoding RNA Tug1.","date":"2020","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32467232","citation_count":19,"is_preprint":false},{"pmid":"28816938","id":"PMC_28816938","title":"Advanced glycation end products promote ChREBP expression and cell proliferation in liver cancer cells by increasing reactive oxygen species.","date":"2017","source":"Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28816938","citation_count":19,"is_preprint":false},{"pmid":"36402191","id":"PMC_36402191","title":"Hepatocyte Kctd17 Inhibition Ameliorates Glucose Intolerance and Hepatic Steatosis Caused by Obesity-induced Chrebp Stabilization.","date":"2022","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/36402191","citation_count":18,"is_preprint":false},{"pmid":"37611830","id":"PMC_37611830","title":"The transcription factor ChREBP links mitochondrial lipidomes to mitochondrial morphology and progression of diabetic kidney disease.","date":"2023","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/37611830","citation_count":18,"is_preprint":false},{"pmid":"21726544","id":"PMC_21726544","title":"ChREBP gene polymorphisms are associated with coronary artery disease in Han population of Hubei province.","date":"2011","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21726544","citation_count":18,"is_preprint":false},{"pmid":"34600826","id":"PMC_34600826","title":"ChREBP deficiency alleviates apoptosis by inhibiting TXNIP/oxidative stress in diabetic nephropathy.","date":"2021","source":"Journal of diabetes and its complications","url":"https://pubmed.ncbi.nlm.nih.gov/34600826","citation_count":17,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50720,"output_tokens":12053,"usd":0.166478,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":23673,"output_tokens":10525,"usd":0.190745,"stage2_stop_reason":"end_turn"},"total_usd":0.357223,"stage1_batch_id":"msgbatch_01BbTCMyrRPyhtEq6b1MdwCN","stage2_batch_id":"msgbatch_011dEed5bbxYvTAaQWKJevxu","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2001,\n      \"finding\": \"WBSCR14 (MLXIPL/ChREBP) encodes a bHLH-leucine zipper transcription factor that heterodimerizes with Mlx to bind the DNA sequence CACGTG (E-box); association with Mlx represses E-box-dependent transcription, analogous to Mad/Max interactions.\",\n      \"method\": \"Heterodimer formation and DNA-binding demonstrated by co-immunoprecipitation and electrophoretic mobility shift assay (EMSA); transcriptional repression confirmed by reporter assay\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — direct biochemical binding assay, EMSA, and reporter assay in a single focused study establishing the core molecular mechanism\",\n      \"pmids\": [\"11230181\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"ChREBP is activated by increased glucose flux: xylulose 5-phosphate (generated via the pentose phosphate pathway) triggers protein phosphatase 2A (PP2A), which dephosphorylates ChREBP, enabling its nuclear import and transcriptional activation of glycolytic and lipogenic genes.\",\n      \"method\": \"Biochemical pathway reconstitution; measurement of xylulose 5-phosphate levels; PP2A activity assays; nuclear fractionation in hepatocytes\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — mechanism replicated and reviewed across multiple laboratories; biochemical reconstitution of the Xu-5-P/PP2A/ChREBP axis\",\n      \"pmids\": [\"16890538\", \"18490833\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Polyunsaturated fatty acids (PUFAs: C18:2, C20:5, C22:6) suppress ChREBP activity by increasing ChREBP mRNA decay and blocking its nuclear translocation (independently of AMPK), whereas saturated and monounsaturated fatty acids have no effect. The PUFA-mediated inhibition is primarily through reduction of xylulose 5-phosphate concentrations.\",\n      \"method\": \"In vivo and in vitro mouse hepatocyte experiments; nuclear fractionation; AMPK-knockout hepatocytes; overexpression of constitutively nuclear ChREBP isoform to rescue PUFA inhibition\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (nuclear fractionation, KO controls, gain-of-function rescue) in a single rigorous study\",\n      \"pmids\": [\"16184193\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"ChREBP nuclear export is regulated by phosphorylation-dependent binding to 14-3-3 proteins: 14-3-3 binds an α-helix (residues 125–135) of the N-terminal domain of ChREBP, facilitated by phosphorylation of nearby Ser-140 and Ser-196. Phosphorylation also enables CRM1-mediated nuclear export, whereas dephosphorylated ChREBP interacts with importin-α for nuclear import; 14-3-3 and importin-α compete for ChREBP binding.\",\n      \"method\": \"In vitro binding assays with synthetic peptides; isothermal titration calorimetry (Kd = 1.1 µM for phospho-Ser-140 peptide); fluorescence spectroscopy; site-directed mutagenesis; nuclear fractionation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — isothermal calorimetry, mutagenesis, and subcellular fractionation in one rigorous biochemical study\",\n      \"pmids\": [\"18606808\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"ChREBP is O-GlcNAcylated in liver cells through interaction with O-GlcNAc transferase (OGT). O-GlcNAcylation stabilizes the ChREBP protein and increases its transcriptional activity toward glycolytic (L-PK) and lipogenic (ACC, FAS, SCD1) target genes in combination with active glucose flux. OGT overexpression increases nuclear ChREBP O-GlcNAc levels and promotes hepatic lipogenesis; OGA overexpression reduces lipogenic protein content and prevents hepatic steatosis in db/db mice.\",\n      \"method\": \"Co-immunoprecipitation of ChREBP with OGT; adenoviral overexpression/inhibition of OGT and OGA in mouse hepatocytes and in vivo; immunoblot for nuclear ChREBP-OGlcNAc\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, in vivo genetic gain/loss-of-function with multiple biochemical readouts, replicated in both cell and animal models\",\n      \"pmids\": [\"21471514\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"ChREBP imports into the nucleus via a classical bipartite nuclear localization signal (NLS) spanning residues 158–190; importin-α binds this NLS, and replacing Lys-159/Lys-190 with alanine abolishes importin-α binding, glucose-stimulated transcriptional activity, and nuclear localization. A secondary 14-3-3 binding site (α3 helix, residues 170–190, phospho-Ser-196) competes with importin-α.\",\n      \"method\": \"In vitro binding assays; site-directed mutagenesis (K159A, K190A); nuclear localization assays; transcriptional reporter assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis combined with biochemical binding and functional transcriptional assays in one rigorous study\",\n      \"pmids\": [\"21665952\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Crystal structure of 14-3-3β bound to the N-terminal regulatory region of ChREBP at 2.4 Å resolution reveals that ChREBP α2 helix (residues 117–137) binds 14-3-3 in a phosphorylation-independent, novel mode distinct from all previously characterized 14-3-3 interactions; structure-based mutagenesis disrupting this interface abolishes complex formation.\",\n      \"method\": \"X-ray crystallography (2.4 Å); structure-based mutagenesis; in vitro binding assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — high-resolution crystal structure with mutagenesis validation in a single rigorous study\",\n      \"pmids\": [\"23086940\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"ChREBP, but not liver X receptors (LXRs), is required for glucose-induced expression of L-PK, ACC, and FAS in mouse liver. LXR stimulation did not promote ChREBP nuclear localization in the absence of increased intrahepatic glucose flux; glucose induction of these genes was identical in LXRα/β knockout vs. wild-type mice; siRNA silencing of ChREBP in LXRα/β-KO hepatocytes abrogated glucose-induced L-PK and ACC expression.\",\n      \"method\": \"LXR knockout mice; LXR agonist treatment; siRNA knockdown of ChREBP; FRET analysis of LXR-cofactor interactions; nuclear fractionation\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis (LXR KO) combined with siRNA knockdown, FRET, and nuclear fractionation with orthogonal methods\",\n      \"pmids\": [\"18292813\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"ChREBP mediates glucose-stimulated pancreatic β-cell proliferation; depletion of ChREBP decreases glucose-stimulated proliferation and cell-cycle accelerator expression, while overexpression amplifies glucose-stimulated proliferation with increases in cyclin gene expression.\",\n      \"method\": \"ChREBP knockout mouse β-cells; siRNA knockdown in INS-1 832/13 cells and primary rat/human β-cells; adenoviral overexpression; BrdU/[3H]thymidine incorporation; FACS; qRT-PCR\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — loss-of-function (KO, siRNA) and gain-of-function (adenovirus) in multiple cell systems with quantitative proliferation readouts\",\n      \"pmids\": [\"22586588\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"A novel, potent ChREBP isoform (ChREBP-β) is transcribed from an alternative promoter in adipose tissue; glucose-mediated activation of canonical ChREBP-α induces ChREBP-β expression. ChREBP-β lacks the N-terminal inhibitory LID domain and is constitutively active. Adipose ChREBP-β is a major determinant of adipose tissue de novo lipogenesis and systemic insulin sensitivity.\",\n      \"method\": \"Identification of alternative promoter by 5′-RACE; adenoviral overexpression and siRNA knockdown in adipocytes; GLUT4-knockout mouse model; measurement of lipogenic rates\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — discovery of isoform with mechanistic characterization, multiple mouse models, and functional lipogenic/insulin sensitivity readouts\",\n      \"pmids\": [\"22466288\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Host cell factor 1 (HCF-1) is a ChREBP-interacting protein; HCF-1 must first be O-GlcNAcylated in response to glucose to bind ChREBP, after which it recruits OGT to O-GlcNAcylate and activate ChREBP. The HCF-1:ChREBP complex occupies lipogenic gene promoters where HCF-1 regulates H3K4 trimethylation and recruits the histone demethylase PHF2 for epigenetic activation.\",\n      \"method\": \"Co-immunoprecipitation; ChIP at lipogenic gene promoters; O-GlcNAc site mapping; genetic knockdown; histone modification assays\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP, ChIP, biochemical O-GlcNAcylation studies, and genetic loss-of-function in one rigorous study\",\n      \"pmids\": [\"31227231\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Site-specific O-GlcNAcylation of ChREBP: Ser839 O-GlcNAcylation is essential for Mlx heterodimerization and enhanced DNA-binding activity, and is also crucial for ChREBP nuclear export via strengthening interactions with CRM1 and 14-3-3. Ser614 O-GlcNAcylation was identified by mass spectrometry. Ser514 phosphorylation under high glucose conditions enhances subsequent O-GlcNAcylation of ChREBP.\",\n      \"method\": \"Chemoenzymatic labeling; metabolic labeling; mass spectrometry; site-directed mutagenesis; co-immunoprecipitation; DNA-binding assays\",\n      \"journal\": \"Molecular & cellular proteomics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mass spectrometry site identification combined with mutagenesis and functional assays in one study\",\n      \"pmids\": [\"28450420\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"c-Myc is required for ChREBP-dependent activation of glucose-responsive genes; glucose promotes co-recruitment of both ChREBP and c-Myc to the Pklr promoter. Depletion of c-Myc activity abolishes glucose-mediated recruitment of HNF4α, ChREBP, and RNA Pol II without affecting basal expression, constitutively bound HNF1α, or histone acetylation.\",\n      \"method\": \"Time-course chromatin immunoprecipitation (ChIP); nuclear run-on transcription assay; small molecule inhibition of c-Myc (10058-F4); reporter assays\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP time-course, nuclear run-on assay, and small-molecule functional epistasis in one study\",\n      \"pmids\": [\"20382893\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"ChREBP (WBSCR14/MLXIPL) is present in rat islets and INS-1 cells; glucose stimulates ChREBP transcription (nuclear run-on); overexpression of ChREBP in INS-1 cells produces a left shift in glucose responsiveness of L-PK expression and enhanced L-PK promoter activity; both endogenous and induced ChREBP bind the L-PK promoter in a glucose-dependent manner.\",\n      \"method\": \"Nuclear run-on experiment; tet-on inducible overexpression system; Northern/Western blot; EMSA (L-PK promoter binding); immunofluorescence\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — nuclear run-on, inducible overexpression, and direct promoter binding assay in INS-1 cells\",\n      \"pmids\": [\"12087089\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"ChREBP expression is induced by mitogenic stimulation and is required for efficient cell proliferation. Suppression of ChREBP redirects glucose metabolism from aerobic glycolysis/lipogenesis/nucleotide biosynthesis toward oxidative phosphorylation, activates p53, and causes cell cycle arrest. In vivo, ChREBP suppression leads to p53-dependent reduction in tumor growth.\",\n      \"method\": \"RNAi-mediated knockdown; metabolic flux measurements; p53 reporter assays; in vivo xenograft tumor model\",\n      \"journal\": \"PNAS\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with multiple metabolic and cell-cycle readouts, including in vivo tumor model\",\n      \"pmids\": [\"19995986\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"In Drosophila, the Mondo (ChREBP ortholog)/Mlx transcriptional network is essential for dietary sugar tolerance; Mlx-null and mondo-reduced larvae have widespread changes in lipid and phospholipid profiles, elevated circulating glucose, and markedly reduced survival on high-sugar diets. Systematic loss-of-function of Mlx target genes identifies Phosphofructokinase 2 (glycolysis), Cabut (KLF transcription factor), and Aldehyde dehydrogenase III as required for sugar tolerance, while fatty acid synthesis is not required and is in fact detrimental.\",\n      \"method\": \"Genetic null mutants; systematic RNAi loss-of-function screen; lipidomics; metabolite measurements\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — systematic genetic screen with multiple orthogonal metabolic readouts in Drosophila; functional conservation with mammalian ChREBP/Mlx\",\n      \"pmids\": [\"23593032\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"ChREBP represses SIRT1 expression in the fed state (high nutrient availability); CREB activates SIRT1 expression during fasting. These opposing transcription factors control SIRT1 expression in a nutrient-sensitive manner across metabolic tissues.\",\n      \"method\": \"Genetic loss-of-function (ChREBP knockout); chromatin immunoprecipitation; reporter assays; metabolic tissue analysis in multiple nutritional states\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChREBP KO with ChIP, but mechanism of direct repression vs. indirect effects not fully dissected in abstract\",\n      \"pmids\": [\"21836635\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ChREBP is activated by fructose-derived hexose-phosphates in liver and is required for fructose-induced induction of glycolytic, lipogenic, and gluconeogenic (G6pc) genes. ChREBP-driven G6PC activity is a major determinant of hepatic glucose production and reduces glucose-6-phosphate levels. This ChREBP/G6PC axis operates independently of FoxO1 and dominates over insulin suppression.\",\n      \"method\": \"ChREBP knockout mice; FoxO1-knockout epistasis; hepatic hexose-phosphate measurements; in vivo fructose gavage; G6PC activity assays; conservation confirmed in human cells\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis (KO of ChREBP and FoxO1), enzymatic activity assays, and metabolite measurements with human validation\",\n      \"pmids\": [\"27669460\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ChREBP and PPARα cooperate to regulate glucose-induced FGF21 expression in the liver; PPARα is required for chromatin accessibility at the Fgf21 promoter and for ChREBP binding to the Fgf21 ChoRE. Hepatic PPARα knockout reduces glucose-mediated FGF21 induction, which is restored by active ChREBP re-expression.\",\n      \"method\": \"ChREBP-KO and PPARα-KO mice; adenoviral ChREBP re-expression; microarray; ChIP for ChREBP at Fgf21 ChoRE; ATAC-seq/chromatin accessibility\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — two KO models with ChIP and chromatin accessibility, plus rescue by ChREBP re-expression\",\n      \"pmids\": [\"29020627\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ChREBP is required for fructose-induced FGF21 secretion; in ChREBP-KO mice, the acute rise in circulating FGF21 following fructose gavage is absent. FGF21 in turn amplifies ChREBP-β and its lipogenic/fructolytic gene targets, constituting a ChREBP–FGF21 feedforward signaling axis.\",\n      \"method\": \"ChREBP-KO mice; FGF21-KO mice; fructose gavage; plasma FGF21 ELISA; stable isotope tracer de novo lipogenesis measurements\",\n      \"journal\": \"Molecular metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — two independent KO mouse models with quantitative metabolic and endocrine measurements\",\n      \"pmids\": [\"28123933\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Intestinal ChREBP directly binds the Glut5 (Slc2a5) promoter and transcriptionally activates GLUT5 expression; ChREBP and its partner Mlx co-activate the Glut5 promoter. Intestine-specific ChREBP KO leads to fructose intolerance with downregulation of GLUT5 and fructolytic genes, while liver-specific KO does not impair fructose tolerance.\",\n      \"method\": \"Tissue-specific ChREBP knockout mice (intestine and liver); ChIP on Glut5 promoter; transient transfection/promoter assay with ChREBP + Mlx in Caco-2BBE cells; high-fructose diet phenotyping\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — tissue-specific KO epistasis, direct ChIP on target promoter, and functional transactivation assay\",\n      \"pmids\": [\"29263303\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Hormone-sensitive lipase (HSL) physically interacts with ChREBP-α (independently of lipase activity), impairing ChREBP-α nuclear translocation and induction of the constitutively active ChREBP-β isoform. Loss of HSL in adipocytes enhances ChREBP-α nuclear entry, drives ChREBP-β-dependent induction of ELOVL6, increases membrane oleic acid, and enhances insulin signaling.\",\n      \"method\": \"Co-immunoprecipitation of HSL and ChREBP; genetic inhibition of HSL in human adipocytes and mouse adipose; siRNA knockdown of ChREBP and ELOVL6; nuclear fractionation; phospholipid analysis\",\n      \"journal\": \"Nature metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, multiple genetic models (human cells and mouse tissue), nuclear fractionation with lipid functional readout\",\n      \"pmids\": [\"32694809\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ChREBP directly binds to the Glut5 promoter in intestinal cells (confirmed by ChIP) and, together with its heterodimer partner Mlx, activates Glut5 promoter activity. ChREBP KO mice exhibit sucrose intolerance and fructose malabsorption with suppression of fructose transport and metabolism gene expression.\",\n      \"method\": \"ChREBP KO mice; ChIP on Glut5 promoter in small intestine; co-transfection reporter assay in Caco-2BBE; RT-PCR; gut microbiota analysis\",\n      \"journal\": \"Metabolism: clinical and experimental\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct ChIP on target promoter, transactivation assay, and genetic KO phenotyping\",\n      \"pmids\": [\"29669261\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"BHLHB2/DEC1 constitutes a negative feedback loop with ChREBP in regulating lipogenesis: ChREBP induces Bhlhb2 expression via a functional ChoRE in the Bhlhb2 promoter, and BHLHB2 in turn inhibits ChREBP-mediated induction of Fasn and Lpk by binding to their ChoRE sequences.\",\n      \"method\": \"Promoter deletion analysis; ChIP assay for BHLHB2 binding to Fasn, Lpk, and Bhlhb2 promoters; overexpression of dominant-active ChREBP; RT-PCR in rat hepatocytes\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP assay and promoter deletion with functional overexpression, single lab\",\n      \"pmids\": [\"18602890\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"mTOR associates with the ChREBP-Mlx complex in pancreatic β-cells and inhibits ChREBP transcriptional activity, leading to decreased TXNIP expression. mTOR deficiency in β-cells increases ChREBP-Mlx-driven TXNIP expression and oxidative stress.\",\n      \"method\": \"Co-immunoprecipitation of mTOR with ChREBP-Mlx; β-cell-specific mTOR knockout mice; TXNIP expression analysis; oxidative stress markers\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP showing complex formation and KO mouse with defined molecular phenotype, single lab\",\n      \"pmids\": [\"28606928\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"SIRT6 physically interacts with ChREBP in hepatocytes and suppresses ChREBP transcriptional activity through direct deacetylation, thereby reducing lipogenic gene expression. SIRT6 liver-specific KO leads to elevated ChREBP protein levels and activity.\",\n      \"method\": \"Co-immunoprecipitation of SIRT6 with ChREBP; deacetylation assay; SIRT6 liver-specific KO mice; Western diet metabolic phenotyping\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular basis of disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, deacetylation assay, and KO mouse with metabolic readout; single lab\",\n      \"pmids\": [\"34425214\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"SMURF2 (E3 ubiquitin ligase) interacts with ChREBP and promotes its ubiquitination and proteasomal degradation. SMURF2 expression inversely correlates with ChREBP levels. AKT acts upstream to suppress SMURF2, thereby protecting ChREBP from degradation. SMURF2-mediated ChREBP degradation reduces aerobic glycolysis and cell proliferation in colorectal cancer cells.\",\n      \"method\": \"Co-immunoprecipitation; ubiquitination assay; SMURF2 overexpression and knockdown; AKT pharmacological inhibition; metabolic flux measurements\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, ubiquitination assay, and gain/loss-of-function with metabolic readouts in cancer cells; single lab\",\n      \"pmids\": [\"31409643\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Flightless I homolog (FLII), a gelsolin superfamily actin-remodeling protein, physically interacts with ChREBP and negatively regulates its transcriptional activity in cancer cells. The C-terminal 227 amino acids of ChREBP (containing the DNA-binding domain) interact with both LRR and GLD domains of FLII. FLII knockdown increases, and overexpression decreases, ChREBP target gene expression.\",\n      \"method\": \"Proteomic pulldown to identify interacting proteins; co-immunoprecipitation; co-localization by immunofluorescence; siRNA knockdown and overexpression of FLII\",\n      \"journal\": \"The international journal of biochemistry & cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — Co-IP, domain mapping, and functional knockdown/overexpression; single lab\",\n      \"pmids\": [\"24055811\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"ChREBP mediates glucose repression of PPARα gene expression in pancreatic β-cells: a constitutively active ChREBP efficiently represses PPARα expression, and siRNA knockdown of ChREBP abrogates glucose repression of PPARα as well as induction of established ChREBP target genes in insulinoma cells and rodent/human islets.\",\n      \"method\": \"Constitutively active ChREBP overexpression; siRNA knockdown of ChREBP; gene expression analysis in insulinoma cells and primary islets; PPARα promoter characterization\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain- and loss-of-function with defined transcriptional readout in multiple cell systems; single lab\",\n      \"pmids\": [\"21282101\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ChREBP controls PPARγ activity in adipocytes in a fatty acid synthase (FASN)-dependent manner: constitutively active ChREBP activates endogenous PPARγ and promotes adipocyte differentiation by transactivating the PPARγ ligand-binding domain. Reducing ChREBP activity by siRNA, low glucose, or dominant-negative ChREBP impairs differentiation.\",\n      \"method\": \"Constitutively active ChREBP and dominant-negative ChREBP overexpression; siRNA knockdown; PPARγ ligand-binding domain reporter assay; adipocyte differentiation assay; FASN inhibitor treatment\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain/loss-of-function with reporter assay and differentiation phenotype; mechanism (FASN-dependent lipid ligand generation) is indirectly inferred\",\n      \"pmids\": [\"26181104\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ChREBP regulates hepatic VLDL secretion primarily through transcriptional activation of microsomal triglyceride transfer protein (MTTP); ChREBP overexpression induces Mttp mRNA and protein, while ChREBP KO markedly reduces VLDL particle number and secretion rates. SHP had negligible effect on Mttp expression under normal conditions and did not affect ChREBP transcriptional activity.\",\n      \"method\": \"Adenoviral overexpression of ChREBP and SHP in rat hepatocytes; promoter reporter assays; Shp-/-, Chrebp-/-, and Chrebp-/-Shp-/- mice; VLDL secretion rate measurements; mRNA/protein analysis\",\n      \"journal\": \"Nutrients\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple KO mouse models and promoter assays; single lab\",\n      \"pmids\": [\"29518948\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"mTORC2 (Rictor) in white adipose tissue controls ChREBP-β expression and de novo lipogenesis: adipocyte-specific deletion of Rictor decreases ChREBP-β expression, reduces adipose DNL, and impairs hepatic insulin sensitivity. mTORC2 promotes ChREBP-β expression in part by controlling glucose uptake.\",\n      \"method\": \"Adipocyte-specific Rictor knockout mice; ChREBP-β mRNA and lipogenic rate measurements; hepatic insulin sensitivity assays; high-fat diet metabolic phenotyping\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — tissue-specific KO with defined molecular and metabolic phenotypes; mechanism (direct vs. indirect mTORC2 → ChREBP-β) partially established\",\n      \"pmids\": [\"27098609\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ChREBP and Myc cooperatively regulate hepatocyte proliferation and metabolism; ChREBP loss confers a proliferative disadvantage to normal murine hepatocytes (unlike Myc loss), and combined loss further impairs proliferation. ChREBP-controlled transcripts encode enzymes in glycolysis, TCA cycle, and β- and ω-FAO, while Myc-controlled transcripts encode glycolytic, glutaminolytic, and sterol biosynthetic enzymes. Both cooperatively upregulate ribosomal protein genes.\",\n      \"method\": \"Chrebp-/- and Myc-/- single and double KO mice; hepatoblastoma models; RNA-Seq; metabolic flux studies (oxidative phosphorylation, FAO, pyruvate dehydrogenase)\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis with RNA-Seq and metabolic flux measurements; single lab\",\n      \"pmids\": [\"30087120\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ChREBP acts as an oncogene in hepatocellular carcinoma (HCC) by transcriptionally activating the PI3K regulatory subunit p85α to sustain PI3K/AKT signaling, while simultaneously rerouting glucose and glutamine metabolic fluxes into fatty acid and nucleic acid synthesis. Pharmacological inhibition of ChREBP by SBI-993 suppresses HCC tumor growth in vivo.\",\n      \"method\": \"ChREBP loss-of-function in HCC cells; ChREBP ChIP-Seq; metabolic flux analysis; p85α promoter assays; SBI-993 pharmacological inhibition in vivo xenograft model\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-Seq, metabolic flux, promoter assay, and in vivo pharmacological inhibition with tumor growth readout\",\n      \"pmids\": [\"38424041\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Retinol saturase (RetSat) functions upstream of ChREBP in liver: depletion of RetSat reduces ChREBP activity, lowering lipogenic gene expression and hepatic/circulating triglycerides. RetSat's effect on ChREBP is independent of its enzymatic product 13,14-dihydroretinol, suggesting a non-catalytic mechanism.\",\n      \"method\": \"Liver-specific RetSat depletion in dietary obese mice; ectopic ChREBP expression rescue; 13,14-dihydroretinol supplementation; hepatic TG and blood glucose measurement\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO with rescue experiment establishing pathway position; mechanism of RetSat→ChREBP connection not fully defined biochemically\",\n      \"pmids\": [\"28855500\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Liver ChREBP protects against fructose-induced glycogenic hepatotoxicity by transcriptionally activating L-type pyruvate kinase (LPK) to channel glucose-6-phosphate away from glycogen synthesis. Liver-specific ChREBP KO causes massive glycogen overload and decreased ATP in fructose-fed mice; hepatic LPK overexpression rescues these phenotypes.\",\n      \"method\": \"Liver-specific ChREBP KO mice; high-fructose diet; hepatic LPK adenoviral overexpression rescue; G6P measurements; ATP content assay; histology\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO with mechanistic rescue by target gene overexpression; multiple metabolic measurements\",\n      \"pmids\": [\"31974143\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ChREBP transcriptionally activates hepatocyte growth factor activator (HGFAC) in mouse and human liver (identified via ChIP-Seq); HGFAC enhances lipid and glucose homeostasis partly through activation of hepatic PPARγ. HGFAC-KO mouse phenotypes are concordant with putative loss-of-function human HGFAC variants.\",\n      \"method\": \"ChREBP ChIP-Seq in mouse liver integrated with human GWAS data; HGFAC gain/loss-of-function mouse models; PPARγ activity assays\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-Seq with KO mouse models and human genomic integration; PPARγ mechanism is partially inferred\",\n      \"pmids\": [\"36413406\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Thyroid hormone receptor β1 (TRβ1) stimulates hepatic lipogenesis through ChREBP: hepatocyte-specific ChREBP KO abolishes TH-mediated induction of the lipogenic program and impairs regulation of fatty acid oxidation. TH regulates ChREBP activation and its recruitment to DNA. This pathway is conserved in human iPSC-derived hepatocytes.\",\n      \"method\": \"Hepatocyte-specific TRβ1 KO and ChREBP KO mice; T3 treatment; ChREBP ChIP; lipogenic gene expression; conservation in human iPSC-derived hepatocytes\",\n      \"journal\": \"Science signaling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two KO mouse models with ChIP and human cell validation; mechanistic details of TH-ChREBP interaction are partially defined\",\n      \"pmids\": [\"34784250\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ChREBP, together with FoxO1, dually regulates TXNIP (thioredoxin-interacting protein) expression in hepatocytes: ChREBP is required for glucose/fed-state induction of TxNIP in liver, while FoxO1 is required for fasting-state induction. Both transcription factors are identified by ChIP and loss-of-function studies in genetically modified mice.\",\n      \"method\": \"ChREBP KO and FoxO1 KO mice; ChIP-qPCR; reporter assays; nutritional state manipulation\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO epistasis with ChIP in two mouse models; single lab\",\n      \"pmids\": [\"33748706\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Hepatocyte KCTD17 promotes ChREBP protein stabilization by inducing degradation of O-GlcNAcase (OGA), thereby increasing O-GlcNAcylated ChREBP levels. SREBP1c induces KCTD17 expression in obesity. Hepatocyte-specific KCTD17 KO in HFD-fed mice improves glucose tolerance and hepatic steatosis; this is reversed by concomitant OGA KO.\",\n      \"method\": \"CRISPR-Cas9 hepatocyte-specific KO (Kctd17, Oga, double KO); AAV delivery; OGA protein stability assay; ChREBP protein level and target gene analysis; HFD metabolic phenotyping\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis with double KO rescue, multiple in vivo metabolic phenotypes, and mechanistic link to OGA/O-GlcNAcylation\",\n      \"pmids\": [\"36402191\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Celastrol directly binds to ChREBP (confirmed by molecular docking, CETSA, DARTS, and mass spectrometry), inhibits ChREBP nuclear translocation, and promotes its proteasomal degradation, thereby repressing TXNIP transcription and ameliorating type 2 diabetes in db/db mice.\",\n      \"method\": \"Molecular docking; cellular thermal shift assay (CETSA); drug affinity responsive target stability (DARTS); mass spectrometry; nuclear fractionation; gain/loss-of-function (ChREBP and TXNIP); db/db mouse model\",\n      \"journal\": \"Phytomedicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — multiple biophysical binding assays (CETSA, DARTS, MS) confirming direct binding, plus nuclear translocation and in vivo phenotype; single lab\",\n      \"pmids\": [\"36603341\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ChREBP induces mitochondrial fragmentation in kidney podocytes through upregulation of ether phospholipid biosynthesis: ChREBP transcriptionally activates Gnpat (glyceronephosphate O-acyltransferase), a critical enzyme in plasmalogen synthesis, and overexpression of GNPAT reverses the protective effect of ChREBP deficiency on mitochondrial fragmentation.\",\n      \"method\": \"Inducible podocyte-specific ChREBP KD in db/db mice; lipidomics; GNPAT overexpression rescue; ChREBP ChIP; electron microscopy for mitochondrial morphology\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KD mouse model with lipidomics, ChIP, and genetic rescue experiment; single lab\",\n      \"pmids\": [\"37611830\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ChREBP and its heterodimer partner Mlx cooperate to activate the Glut5 promoter in intestinal cells; ChIP assay demonstrates direct binding of ChREBP to the Glut5 ChoRE in small intestine, but not to the NHE3 promoter.\",\n      \"method\": \"ChIP assay in mouse small intestine; co-transfection promoter reporter assay in Caco-2BBE cells with ChREBP + Mlx\",\n      \"journal\": \"Metabolism: clinical and experimental\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct ChIP on target promoter plus transactivation assay; single lab\",\n      \"pmids\": [\"29669261\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ChREBP directly regulates de novo lipogenesis in interplay with SREBP-1c: both transcription factors are required for coordinated postprandial induction of glycolytic and lipogenic mRNAs. ChREBP mediates glucose induction of both glycolytic and lipogenic genes, while SREBP-1c mediates insulin induction of lipogenic genes. ChREBP is also required for normal SREBP-1c mRNA and protein levels in the fed state.\",\n      \"method\": \"Liver-specific ChREBP KO mice; AAV-mediated nuclear SREBP-1c restoration; Scap-deficient mice (lack active SREBPs); sucrose refeeding paradigm; mRNA and protein measurements\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis (two KO models), AAV-mediated rescue, and double-conditional approach establishing pathway co-dependence\",\n      \"pmids\": [\"29335275\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"High glucose activates nuclear translocation of ChREBP in retinal pigment epithelial (RPE) cells under normoxia, and ChREBP associates with the HIF-1α gene promoter, driving HIF-1α and VEGF expression. This phenomenon is cell-type specific (not observed in lens epithelial or HeLa cells).\",\n      \"method\": \"Immunofluorescence for ChREBP nuclear localization; ChIP for ChREBP at HIF-1α promoter; ELISA for VEGF; RT-PCR; immunoblot\",\n      \"journal\": \"Advances in experimental medicine and biology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single ChIP and immunofluorescence study in a single cell type, limited functional follow-up\",\n      \"pmids\": [\"24664750\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ChREBP (MLXIPL) is a glucose-responsive bHLH-leucine zipper transcription factor that heterodimerizes with Mlx to bind carbohydrate response elements (ChoRE) and transcriptionally activate glycolytic and lipogenic genes; its activity is tightly controlled by nucleocytoplasmic shuttling regulated through phosphorylation (by PKA/AMPK during fasting, reversed by PP2A activated by xylulose 5-phosphate during feeding), interaction of its N-terminal regulatory domain with 14-3-3 proteins (retaining it in the cytosol) and importin-α (driving nuclear import), and post-translational modifications including O-GlcNAcylation (which stabilizes the protein and enhances DNA binding and Mlx heterodimerization) and ubiquitination (mediated by SMURF2 for proteasomal degradation); a potent, constitutively active isoform ChREBP-β lacking the N-terminal inhibitory domain is induced from an alternative promoter by ChREBP-α; in the nucleus ChREBP cooperates with cofactors including HCF-1 (which recruits OGT and the demethylase PHF2 for epigenetic activation), c-Myc, PPARα, and SIRT6 (which deacetylates and suppresses ChREBP), and regulates a broad transcriptional program encompassing lipogenesis, glycolysis, gluconeogenesis (via G6PC), FGF21 secretion, fructose transport (GLUT5), TXNIP, and mitochondrial lipid remodeling across liver, adipose tissue, intestine, pancreatic β-cells, and kidney.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"MLXIPL (ChREBP) is a glucose-responsive basic helix-loop-helix-leucine zipper transcription factor that couples cellular carbohydrate flux to the transcriptional control of glycolytic and lipogenic gene programs across liver, adipose, intestine, pancreatic \\u03b2-cells, and kidney [#0, #13, #7]. It functions as an obligate heterodimer with Mlx, binding E-box/carbohydrate response element (ChoRE) sequences in target promoters such as L-PK and Glut5 [#0, #13, #20]. Its activity is governed by glucose-flux-driven nucleocytoplasmic shuttling: xylulose-5-phosphate activates PP2A to dephosphorylate ChREBP and permit nuclear entry, while polyunsaturated fatty acids suppress activity by lowering xylulose-5-phosphate and blocking nuclear translocation [#1, #2]. Subcellular distribution is set by a competition at the N-terminal regulatory domain in which phosphorylation promotes 14-3-3 binding and CRM1-dependent export, whereas the dephosphorylated form engages importin-\\u03b1 at a bipartite NLS for nuclear import [#3, #5, #6]. Site-specific O-GlcNAcylation, enabled by OGT recruited through glucose-dependent O-GlcNAcylated HCF-1, stabilizes ChREBP and enhances Mlx heterodimerization and DNA binding, with HCF-1 also recruiting PHF2 for epigenetic activation of lipogenic promoters [#4, #10, #11]. Protein abundance is additionally controlled by SMURF2-mediated ubiquitination and by KCTD17, which raises O-GlcNAcylated ChREBP by destabilizing OGA [#26, #39]. A constitutively active isoform, ChREBP-\\u03b2, lacking the N-terminal inhibitory domain, is induced from an alternative promoter downstream of glucose-activated ChREBP-\\u03b1 and drives adipose de novo lipogenesis and systemic insulin sensitivity [#9]. In the nucleus ChREBP cooperates with c-Myc and PPAR\\u03b1 to activate glucose-responsive and FGF21 genes and is restrained by SIRT6 deacetylation [#12, #18, #25]. Beyond lipogenesis, ChREBP governs fructose handling via GLUT5 and the LPK/G6PC axes, drives a ChREBP\\u2013FGF21 feedforward loop, controls TXNIP, MTTP-dependent VLDL secretion, and mitochondrial lipid remodeling, and acts as an oncogenic driver of aerobic glycolysis and proliferation in hepatocellular and colorectal cancers [#17, #19, #20, #30, #33, #41].\",\n  \"teleology\": [\n    {\n      \"year\": 2001,\n      \"claim\": \"Established the core molecular identity of ChREBP as a bHLH-leucine zipper factor that heterodimerizes with Mlx to bind E-box DNA, defining the obligate partnership underlying all downstream activity.\",\n      \"evidence\": \"Co-immunoprecipitation, EMSA, and reporter assays demonstrating Mlx heterodimerization and CACGTG binding\",\n      \"pmids\": [\"11230181\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Initial study reported E-box repression rather than the activation later shown at ChoREs\", \"Did not define glucose-responsiveness mechanism\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Showed ChREBP is glucose-regulated in pancreatic islet cells and binds the L-PK promoter in a glucose-dependent manner, linking the factor to a physiological metabolic readout.\",\n      \"evidence\": \"Nuclear run-on, inducible overexpression, and EMSA in INS-1 cells and rat islets\",\n      \"pmids\": [\"12087089\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the upstream glucose-sensing biochemistry\", \"Mechanism of nuclear translocation not addressed\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Defined the upstream metabolic signal activating ChREBP, identifying xylulose-5-phosphate/PP2A-mediated dephosphorylation as the switch enabling nuclear import.\",\n      \"evidence\": \"Biochemical pathway reconstitution, PP2A activity assays, and nuclear fractionation in hepatocytes\",\n      \"pmids\": [\"16890538\", \"18490833\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Precise phosphosites controlled by PP2A not fully mapped here\", \"Did not address competing import/export machinery\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Identified PUFAs as physiological inhibitors acting through reduced xylulose-5-phosphate and blocked nuclear translocation, defining nutrient-specific negative regulation independent of AMPK.\",\n      \"evidence\": \"Mouse hepatocyte in vivo/in vitro studies, AMPK-KO controls, and constitutively nuclear isoform rescue\",\n      \"pmids\": [\"16184193\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve direct lipid sensing vs. purely metabolite-mediated effects\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Resolved the molecular basis of cytoplasmic retention versus nuclear import as a phosphorylation-dependent competition between 14-3-3 and importin-\\u03b1 at the N-terminal regulatory domain.\",\n      \"evidence\": \"Synthetic peptide binding, isothermal titration calorimetry, mutagenesis, and nuclear fractionation\",\n      \"pmids\": [\"18606808\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not yet provide structural detail of the 14-3-3 interface\", \"Kinases responsible for specific phosphosites not all defined\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Established genetic epistasis placing ChREBP, not LXR, as the essential transducer of glucose-induced lipogenic gene expression in liver.\",\n      \"evidence\": \"LXR\\u03b1/\\u03b2 knockout mice, ChREBP siRNA, FRET, and nuclear fractionation\",\n      \"pmids\": [\"18292813\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not exclude LXR contributions under other conditions\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Defined a cofactor requirement, showing c-Myc is needed for glucose-stimulated co-recruitment of ChREBP and the transcriptional machinery to the Pklr promoter.\",\n      \"evidence\": \"Time-course ChIP, nuclear run-on, and small-molecule c-Myc inhibition\",\n      \"pmids\": [\"20382893\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Order of recruitment vs. direct interaction not fully resolved\", \"Generality across other ChoRE genes not tested\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Mapped the bipartite NLS bound by importin-\\u03b1 and a competing secondary 14-3-3 site, mechanistically detailing the nuclear import determinants required for glucose-stimulated activity.\",\n      \"evidence\": \"Site-directed mutagenesis (K159A, K190A), binding assays, and transcriptional reporters\",\n      \"pmids\": [\"21665952\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo contribution of individual residues not tested in animals\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Identified O-GlcNAcylation as a glucose-coupled modification that stabilizes ChREBP and enhances its lipogenic transcriptional output, linking nutrient flux to protein stability.\",\n      \"evidence\": \"Reciprocal Co-IP with OGT and in vivo adenoviral OGT/OGA gain/loss-of-function in mouse liver\",\n      \"pmids\": [\"21471514\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific O-GlcNAc sites not mapped in this study\", \"Interplay with phosphorylation not yet defined\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Extended the regulatory network by showing ChREBP transcriptionally represses SIRT1 in the fed state, positioning it within nutrient-sensitive deacetylase signaling.\",\n      \"evidence\": \"ChREBP-KO mice, ChIP, and reporter assays across nutritional states\",\n      \"pmids\": [\"21836635\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs. indirect repression not fully dissected\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Demonstrated ChREBP mediates glucose repression of PPAR\\u03b1 in \\u03b2-cells, broadening its role beyond gene activation to nutrient-dependent gene silencing.\",\n      \"evidence\": \"Constitutively active ChREBP and siRNA knockdown in insulinoma cells and islets\",\n      \"pmids\": [\"21282101\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct promoter binding not definitively shown\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Discovered the constitutively active ChREBP-\\u03b2 isoform induced by ChREBP-\\u03b1 from an alternative promoter, revealing a feedforward amplification mechanism driving adipose lipogenesis and insulin sensitivity.\",\n      \"evidence\": \"5'-RACE promoter mapping, adenoviral and siRNA manipulation in adipocytes, and GLUT4-KO mouse model\",\n      \"pmids\": [\"22466288\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Regulation of ChREBP-\\u03b2 promoter choice not fully defined\", \"Tissue-specific control of isoform balance unresolved\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Provided the crystal structure of 14-3-3\\u03b2 bound to the ChREBP N-terminal regulatory helix, revealing a novel phosphorylation-independent binding mode for cytoplasmic retention.\",\n      \"evidence\": \"X-ray crystallography at 2.4 \\u00c5 with structure-based mutagenesis\",\n      \"pmids\": [\"23086940\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Reconciliation with phosphorylation-dependent 14-3-3 binding at other sites not fully integrated\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Established ChREBP as a driver of glucose-stimulated \\u03b2-cell proliferation through cell-cycle gene induction, connecting metabolic sensing to proliferative control.\",\n      \"evidence\": \"ChREBP-KO, siRNA, and adenoviral overexpression in \\u03b2-cell systems with proliferation readouts\",\n      \"pmids\": [\"22586588\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct cyclin promoter targets not mapped\", \"Relationship to mitogenic ChREBP role in other tissues unclear\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Linked ChREBP to proliferation and tumor growth, showing its loss redirects glucose metabolism toward oxidative phosphorylation and activates p53-dependent arrest.\",\n      \"evidence\": \"RNAi knockdown, metabolic flux analysis, p53 reporters, and xenograft tumor model\",\n      \"pmids\": [\"19995986\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism connecting ChREBP loss to p53 activation not defined\", \"Direct vs. metabolic indirect effect on proliferation unresolved\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Demonstrated evolutionary conservation of the Mondo/Mlx network in dietary sugar tolerance and showed glycolytic, not lipogenic, targets are the critical effectors in Drosophila.\",\n      \"evidence\": \"Genetic null mutants, systematic RNAi screen, lipidomics, and metabolite measurements\",\n      \"pmids\": [\"23593032\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct translation of dispensable lipogenesis to mammals not established\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Identified FLII as a direct interactor that negatively regulates ChREBP via its DNA-binding domain, adding an actin-remodeling protein to the repressor set in cancer cells.\",\n      \"evidence\": \"Proteomic pulldown, Co-IP, domain mapping, and FLII gain/loss-of-function\",\n      \"pmids\": [\"24055811\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological context of FLII regulation not established\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Defined a negative feedback loop in which ChREBP induces BHLHB2/DEC1, which in turn represses ChREBP lipogenic targets, providing autoregulatory damping of lipogenesis.\",\n      \"evidence\": \"Promoter deletion, ChIP, and dominant-active ChREBP overexpression in rat hepatocytes\",\n      \"pmids\": [\"18602890\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo physiological relevance not established\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Showed ChREBP controls PPAR\\u03b3 activity and adipocyte differentiation in a FASN-dependent manner, implicating ChREBP-driven lipid ligand generation in nuclear receptor activation.\",\n      \"evidence\": \"Constitutively active/dominant-negative ChREBP, siRNA, PPAR\\u03b3 LBD reporter, and FASN inhibition\",\n      \"pmids\": [\"26181104\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"The endogenous FASN-derived ligand not identified\", \"Mechanism inferred indirectly\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Established ChREBP as the dominant transducer of fructose-induced glycolytic, lipogenic, and gluconeogenic gene expression, including a G6PC axis controlling hepatic glucose production independent of FoxO1.\",\n      \"evidence\": \"ChREBP-KO and FoxO1-KO epistasis, hexose-phosphate measurements, G6PC activity assays, and human validation\",\n      \"pmids\": [\"27669460\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Sensing of fructose-derived hexose-phosphates not mechanistically resolved\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identified ChREBP as required for fructose-induced FGF21 secretion and revealed a FGF21\\u2192ChREBP-\\u03b2 feedforward loop coupling lipogenesis to endocrine signaling.\",\n      \"evidence\": \"ChREBP-KO and FGF21-KO mice, plasma FGF21 ELISA, and isotope tracer lipogenesis measurements\",\n      \"pmids\": [\"28123933\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular route of FGF21 feedback onto ChREBP-\\u03b2 not defined\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Placed mTORC2 upstream of ChREBP-\\u03b2 in white adipose tissue, linking nutrient-sensitive kinase signaling to adipose lipogenesis and hepatic insulin sensitivity.\",\n      \"evidence\": \"Adipocyte-specific Rictor-KO mice with lipogenic and insulin-sensitivity phenotyping\",\n      \"pmids\": [\"27098609\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs. glucose-uptake-mediated control of ChREBP-\\u03b2 not fully separated\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Mapped functional O-GlcNAc sites (Ser839, Ser614) and showed Ser839 modification is essential for Mlx heterodimerization, DNA binding, and CRM1/14-3-3-mediated export, integrating glycosylation with phosphorylation crosstalk.\",\n      \"evidence\": \"Chemoenzymatic and metabolic labeling, mass spectrometry, mutagenesis, Co-IP, and DNA-binding assays\",\n      \"pmids\": [\"28450420\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo physiological impact of individual sites not tested\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identified PPAR\\u03b1 as a required partner establishing chromatin accessibility for ChREBP binding at the Fgf21 ChoRE, defining a cooperative cofactor mechanism for glucose-induced FGF21.\",\n      \"evidence\": \"ChREBP-KO and PPAR\\u03b1-KO mice, ChIP, ATAC-seq, and ChREBP re-expression rescue\",\n      \"pmids\": [\"29020627\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether PPAR\\u03b1 acts at other ChREBP targets not addressed\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Showed mTOR associates with the ChREBP-Mlx complex in \\u03b2-cells and restrains TXNIP expression, identifying a kinase-complex interaction modulating oxidative stress.\",\n      \"evidence\": \"Co-IP and \\u03b2-cell-specific mTOR-KO mice with TXNIP and oxidative stress readouts\",\n      \"pmids\": [\"28606928\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct phosphorylation of complex components not shown\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Positioned retinol saturase (RetSat) as a non-catalytic upstream activator of hepatic ChREBP, expanding the set of upstream regulators of lipogenic ChREBP activity.\",\n      \"evidence\": \"Liver-specific RetSat depletion with ChREBP rescue and dihydroretinol supplementation\",\n      \"pmids\": [\"28855500\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Biochemical mechanism of RetSat\\u2192ChREBP connection undefined\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Established intestinal ChREBP as a direct activator of the Glut5 fructose transporter, demonstrating tissue-specific control of fructose absorption distinct from hepatic functions.\",\n      \"evidence\": \"Intestine- and liver-specific ChREBP-KO mice, Glut5 promoter ChIP, and Caco-2BBE transactivation assays\",\n      \"pmids\": [\"29263303\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Regulation of intestinal ChREBP isoform balance not addressed\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Confirmed direct ChREBP/Mlx activation of the Glut5 ChoRE in intestine with target specificity, reinforcing the fructose-malabsorption phenotype of ChREBP loss.\",\n      \"evidence\": \"ChIP on Glut5 vs. NHE3 promoters and Caco-2BBE reporter assays in ChREBP-KO mice\",\n      \"pmids\": [\"29669261\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab finding overlapping prior intestinal study\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Defined the ChREBP\\u2013SREBP-1c division of labor in postprandial lipogenesis, showing ChREBP mediates glucose induction and supports SREBP-1c levels in the fed state.\",\n      \"evidence\": \"Liver-specific ChREBP-KO, AAV nuclear SREBP-1c restoration, and Scap-deficient mice\",\n      \"pmids\": [\"29335275\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct physical interaction between the two factors not established\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identified MTTP as the principal ChREBP target governing hepatic VLDL secretion, linking ChREBP to lipoprotein export.\",\n      \"evidence\": \"Adenoviral ChREBP/SHP, promoter reporters, and Chrebp/Shp single and double KO mice with VLDL secretion rates\",\n      \"pmids\": [\"29518948\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct ChoRE in Mttp promoter not definitively mapped\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Showed ChREBP and Myc cooperatively program hepatocyte proliferation and metabolism, with distinct and shared transcriptional outputs including ribosomal genes.\",\n      \"evidence\": \"Chrebp and Myc single/double KO mice, hepatoblastoma models, RNA-Seq, and metabolic flux studies\",\n      \"pmids\": [\"30087120\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether cooperation reflects direct co-binding not established\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Defined HCF-1 as a glucose-sensitive cofactor that, after its own O-GlcNAcylation, recruits OGT to ChREBP and PHF2 for epigenetic activation at lipogenic promoters, mechanistically linking glucose to chromatin modification.\",\n      \"evidence\": \"Co-IP, ChIP, O-GlcNAc site mapping, knockdown, and histone modification assays\",\n      \"pmids\": [\"31227231\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Generality across non-lipogenic ChREBP targets not tested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identified SMURF2 as the E3 ligase driving ChREBP ubiquitination and degradation, with AKT acting upstream, defining a degradation arm controlling ChREBP-dependent glycolysis in cancer.\",\n      \"evidence\": \"Co-IP, ubiquitination assays, SMURF2 gain/loss-of-function, and AKT inhibition in colorectal cancer cells\",\n      \"pmids\": [\"31409643\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Ubiquitination site on ChREBP not mapped\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Revealed a protective hepatic function in which ChREBP-driven LPK channels glucose-6-phosphate away from glycogen, preventing fructose-induced glycogenic hepatotoxicity.\",\n      \"evidence\": \"Liver-specific ChREBP-KO with high-fructose diet and hepatic LPK overexpression rescue\",\n      \"pmids\": [\"31974143\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of G6P partitioning beyond LPK not addressed\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Established SIRT6 as a direct negative regulator that deacetylates and suppresses ChREBP, restraining lipogenic gene expression.\",\n      \"evidence\": \"Co-IP, deacetylation assays, and SIRT6 liver-specific KO mice with Western-diet phenotyping\",\n      \"pmids\": [\"34425214\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific deacetylated lysines not mapped\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Defined a dual ChREBP/FoxO1 regulation of hepatic TXNIP across fed and fasted states, establishing nutrient-state-specific control of a shared target.\",\n      \"evidence\": \"ChREBP-KO and FoxO1-KO mice with ChIP-qPCR and reporter assays\",\n      \"pmids\": [\"33748706\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of state-specific switching between the two factors unresolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Placed ChREBP downstream of thyroid hormone receptor TR\\u03b21 in driving hepatic lipogenesis, showing TH regulates ChREBP activation and DNA recruitment.\",\n      \"evidence\": \"Hepatocyte-specific TR\\u03b21-KO and ChREBP-KO mice, T3 treatment, ChREBP ChIP, and human iPSC-hepatocyte validation\",\n      \"pmids\": [\"34784250\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs. indirect TH-mediated ChREBP activation not fully defined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identified KCTD17 as a stabilizer of ChREBP that acts by promoting OGA degradation to elevate ChREBP O-GlcNAcylation, integrating the SREBP1c\\u2013KCTD17 axis with ChREBP stability in obesity.\",\n      \"evidence\": \"CRISPR hepatocyte-specific single and double KO (Kctd17, Oga), AAV delivery, and HFD metabolic phenotyping\",\n      \"pmids\": [\"36402191\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct KCTD17\\u2013OGA mechanism vs. broader effects not fully separated\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Demonstrated direct small-molecule targeting of ChREBP by celastrol, which blocks nuclear translocation and promotes degradation to repress TXNIP and ameliorate diabetes, providing pharmacological validation of ChREBP as a target.\",\n      \"evidence\": \"Molecular docking, CETSA, DARTS, mass spectrometry, nuclear fractionation, and db/db mouse model\",\n      \"pmids\": [\"36603341\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Binding site on ChREBP not defined\", \"Selectivity vs. other targets not established\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identified a ChREBP target (HGFAC) connecting glucose-sensing transcription to systemic lipid and glucose homeostasis via hepatic PPAR\\u03b3, with concordance between mouse and human genetics.\",\n      \"evidence\": \"ChREBP ChIP-Seq integrated with human GWAS and HGFAC gain/loss-of-function mouse models\",\n      \"pmids\": [\"36413406\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"PPAR\\u03b3 activation mechanism partially inferred\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Linked ChREBP to mitochondrial morphology in kidney podocytes through transcriptional activation of Gnpat and ether phospholipid synthesis, extending its remit to organelle remodeling in diabetic nephropathy.\",\n      \"evidence\": \"Inducible podocyte-specific ChREBP knockdown in db/db mice, lipidomics, ChIP, GNPAT rescue, and EM\",\n      \"pmids\": [\"37611830\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Generality of ether-lipid mechanism to other tissues unknown\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Defined ChREBP as an oncogenic driver in hepatocellular carcinoma that sustains PI3K/AKT signaling via p85\\u03b1 and reroutes glucose/glutamine flux, with pharmacological inhibition suppressing tumor growth.\",\n      \"evidence\": \"ChREBP loss-of-function, ChIP-Seq, metabolic flux analysis, p85\\u03b1 promoter assays, and SBI-993 in vivo xenografts\",\n      \"pmids\": [\"38424041\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Therapeutic window and selectivity of inhibition not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the multiple regulatory layers \\u2014 phosphorylation, O-GlcNAcylation, acetylation, 14-3-3/importin shuttling, ubiquitination, and cofactor recruitment \\u2014 are integrated in real time to set ChREBP output in a tissue- and nutrient-specific manner remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified quantitative model linking PTM crosstalk to transcriptional output\", \"Tissue-specific isoform and cofactor balance not systematically mapped\", \"Structural basis of full-length ChREBP-Mlx ChoRE engagement undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 7, 13, 17, 20, 33]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 11, 13, 20]},\n      {\"term_id\": \"GO:0140297\", \"supporting_discovery_ids\": [10, 12, 18]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [1, 3, 5, 13]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [2, 3, 5, 21]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [1, 4, 7, 17, 35, 43]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 10, 12, 18]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [1, 2, 17]}\n    ],\n    \"complexes\": [\"ChREBP-Mlx heterodimer\"],\n    \"partners\": [\"MLX\", \"YWHAB\", \"HCFC1\", \"OGT\", \"MYC\", \"SIRT6\", \"SMURF2\", \"LIPE\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":9,"faith_total":9,"faith_pct":100.0}}